Document:

EX-10.7

 Exhibit 10.7 

LEGEND BIOTECH CORPORATION 

2020 RESTRICTED SHARES PLAN 

ARTICLE 1 
 PURPOSE

 The purpose of the Legend Biotech Corporation 2020 Restricted Shares Plan (the “Plan”) is to promote the success and
enhance the value of Legend Biotech Corporation, an exempted company incorporated under the laws of the Cayman Islands (the “Company”), by linking the personal interests of the members of the Board, Employees, and Consultants to
those of the Company’s shareholders and by providing such individuals with an incentive for outstanding performance to generate superior returns to the Company’s shareholders. The Plan is further intended to provide flexibility to the
Company in its ability to motivate, attract, and retain the services of members of the Board, Employees, and Consultants upon whose judgment, interest, and special effort the successful conduct of the Company’s operation is largely dependent.

 ARTICLE 2 

DEFINITIONS AND CONSTRUCTION 

Wherever the following terms are used in the Plan, they shall have the meanings specified below, unless the context clearly indicates
otherwise. The singular pronoun shall include the plural where the context so indicates. 
 2.1    “Applicable
Laws” means the legal requirements relating to the Plan and the Awards under applicable provisions of the corporate, securities, tax and other laws, rules, regulations and government orders, and the rules of any applicable stock exchange or
national market system, of any jurisdiction applicable to Awards granted to residents therein. 

2.2    “Award” means a Restricted Share or Restricted Share Unit award granted to a Participant pursuant
to the Plan. 
 2.3    “Award Agreement” means any written agreement, contract, or other instrument or
document evidencing an Award, including through electronic medium. 
 2.4    “Board” means the Board of
Directors of the Company. 
 2.5    “Code” means the Internal Revenue Code of 1986 of the United
States, as amended. 
 2.6    “Committee” means the Board or a committee of the Board described in
Article 9. 
 2.7    “Consultant” means any consultant or adviser if: (a) the consultant or
adviser renders bona fide services to a Service Recipient; (b) the services rendered by the consultant or adviser are not in connection with the offer or sale of securities in a capital-raising transaction and do not directly or indirectly
promote or maintain a market for the Company’s securities; and (c) the consultant or adviser is a natural person who has contracted directly with the Service Recipient to render such services. 

2.8    “Corporate Transaction”, unless otherwise defined in an Award Agreement, means any of the
following transactions, provided, however, that the Committee shall determine under (d) and (e) whether multiple transactions are related, and its determination shall be final, binding and conclusive: 

(a)    an amalgamation, arrangement or consolidation or scheme of arrangement (i) in which the Company is not the
surviving entity, except for a transaction the principal purpose of which is to change the jurisdiction in which the Company is incorporated or (ii) following which the holders of the voting securities of the Company do not continue to hold
more than 50% of the combined voting power of the voting securities of the surviving entity; 

  
 1. 

 (b)    the sale, transfer or other disposition of all or substantially
all of the assets of the Company; 
 (c)    the complete liquidation or dissolution of the Company; 

(d)    any reverse takeover or series of related transactions culminating in a reverse takeover (including, but not
limited to, a tender offer followed by a reverse takeover) in which the Company is the surviving entity but (A) the Company’s equity securities outstanding immediately prior to such takeover are converted or exchanged by virtue of the
takeover into other property, whether in the form of securities, cash or otherwise, or (B) in which securities possessing more than fifty percent (50%) of the total combined voting power of the Company’s outstanding securities are
transferred to a person or persons different from those who held such securities immediately prior to such takeover or the initial transaction culminating in such takeover, but excluding any such transaction or series of related transactions that
the Committee determines shall not be a Corporate Transaction; or 
 (e)    acquisition in a single or series of related
transactions by any person or related group of persons (other than the Company or by a Company-sponsored employee benefit plan) of beneficial ownership (within the meaning of Rule 13d-3 of the Exchange Act) of
securities possessing more than fifty percent (50%) of the total combined voting power of the Company’s outstanding securities but excluding any such transaction or series of related transactions that the Committee determines shall not be
a Corporate Transaction. 
 2.9    “Disability”, unless otherwise defined in an Award Agreement, means
that the Participant qualifies to receive long-term disability payments under the long-term disability insurance program, as it may be amended from time to time, of the Service Recipient to which the Participant provides services regardless of
whether the Participant is covered by such policy. If the Service Recipient to which the Participant provides service does not have a long-term disability plan in place, “Disability” means that a Participant has been rendered permanently
unable to carry out the responsibilities and functions of any position in the Company by reason of any medically determinable physical or mental impairment as documented by a hospital facility. A Participant will not be considered to have incurred a
Disability unless he or she furnishes proof of such impairment sufficient to satisfy the Committee in its discretion. 

2.10    “Effective Date” shall have the meaning set forth in Section 10.1. 

2.11    “Employee” means any person, including an officer or a member of the board of directors of the
Company or any Parent or Subsidiary of the Company, who is in the employment of a Service Recipient, subject to the control and direction of the Service Recipient as to both the work to be performed and the manner and method of performance. The
payment of a director’s fee by a Service Recipient shall not be sufficient to constitute “employment” by the Service Recipient. 

2.12    “Exchange Act” means the Securities Exchange Act of 1934 of the United States, as amended. 

2.13    “Fair Market Value” means, as of any date, the value of Shares determined as follows: 

(a)    If the Shares are listed on one or more established stock exchanges or national market systems, including without
limitation, The New York Stock Exchange and The Nasdaq Stock Market, the Fair Market Value of a Share shall be the closing sales price for such Shares (or the closing bid, if no sales were reported) as quoted on the principal exchange or system on
which the Shares are listed (as determined by the Committee) on the date of determination (or, if no closing sales price or closing bid was reported on that date, as applicable, on the last trading date such closing sales price or closing bid was
reported), as reported in The Wall Street Journal or such other source as the Committee deems reliable; 
 (b)    If the
Shares are regularly quoted on an automated quotation system (including the OTC Bulletin Board) or by a recognized securities dealer, the Fair Market Value of a Share shall be 

  
 2. 

 
the closing sales price for such Shares as quoted on such system or by such securities dealer on the date of determination, but if selling prices are not reported, the Fair Market Value of a
Share shall be the mean between the high bid and low asked prices for the Shares on the date of determination (or, if no such prices were reported on that date, on the last date such prices were reported), as reported in The Wall Street Journal or
such other source as the Committee deems reliable; or 
 (c)    In the absence of an established market for the Shares
of the type described in (a) and (b), above, the Fair Market Value thereof shall be determined by the Committee in good faith and in its discretion by reference to (i) the placing price of the latest private placement of the Shares and the
development of the Company’s business operations and the general economic and market conditions since such latest private placement, (ii) other third party transactions involving the Shares and the development of the Company’s
business operations and the general economic and market conditions since such transactions, (iii) an independent valuation of the Shares, or (iv) such other methodologies or information as the Committee determines to be indicative of Fair
Market Value and relevant. 
 2.14    “Independent Director” means (i) before the Shares or other
securities representing the Shares are listed on a stock exchange, a member of the Board who is a Non-Employee Director; and (ii) after the Shares or other securities representing the Shares are listed on
a stock exchange, a member of the Board who meets the independence standards under the applicable corporate governance rules of the stock exchange. 

2.15    “Market Standoff Period” means the 180-day period (or
such longer period as may be agreed to in writing by the Company) following the effective date of a registration statement of the Company filed under the Securities Act in connection with any initial public offering of Shares. 

2.16    “Non-Employee Director” means a member of the Board who
qualifies as a “Non-Employee Director” as defined in Rule 16b-3(b)(3) of the Exchange Act, or any successor definition adopted by the Board. 

2.17    “Participant” means a person who, as a member of the Board, Consultant or Employee, has been
granted an Award pursuant to the Plan. 
 2.18    “Parent” means a parent corporation under
Section 424(e) of the Code. 
 2.19    “Plan” means this Legend Biotech Corporation 2020
Restricted Shares Plan, as it may be amended from time to time. 
 2.20    “Related Entity” means any
business, corporation, partnership, limited liability company or other entity in which the Company, a Parent or Subsidiary of the Company holds a substantial ownership interest, directly or indirectly, but which is not a Subsidiary and which the
Board designates as a Related Entity for purposes of the Plan. 
 2.21    “Restricted Share” means a
Share awarded to a Participant pursuant to Article 5 that is subject to certain restrictions and may be subject to risk of forfeiture. 

2.22    “Restricted Share Unit” means the right granted to a Participant pursuant to Article 6 to receive
a Share at a future date. 
 2.23    “Securities Act” means the Securities Act of 1933 of the United
States, as amended. 
 2.24    “Service Recipient” means the Company, any Parent or Subsidiary of the
Company and any Related Entity to which a Participant provides services as an Employee, a Consultant or a Director. 

2.25    “Share” means ordinary shares in the capital of the Company, and such other securities of the
Company that may be substituted for Shares pursuant to Article 8. 
 2.26    “Subsidiary” means any
corporation or other entity of which a majority of the outstanding voting shares or voting power is beneficially owned directly or indirectly by the Company. 

  
 3. 

 2.27    “Trading Date” means the closing of the first
sale to the general public of the Shares pursuant to a registration statement filed with and declared effective by the U.S. Securities and Exchange Commission under the Securities Act. 

ARTICLE 3 
 SHARES
SUBJECT TO THE PLAN 
 3.1    Number of Shares. 

(a)    Subject to the provisions of Article 9 and Section 3.1(b), the maximum aggregate number of Shares, which may
be issued pursuant to all Awards granted under the Plan, shall be equal to 11,000,000 Shares. 
 (b)    To the extent
that an Award terminates, expires, or lapses for any reason, any Shares subject to the Award shall again be available for the grant of an Award pursuant to the Plan. To the extent permitted by Applicable Laws, Shares issued in assumption of, or in
substitution for, any outstanding awards of any entity acquired in any form or combination by the Company or any Parent or Subsidiary of the Company shall not be counted against Shares available for grant pursuant to the Plan. Shares delivered by
the Participant or withheld by the Company upon the vesting of any Award under the Plan, in payment of the purchase price thereof or tax withholding thereon, may again be granted or awarded hereunder, subject to the limitations of
Section 3.1(a). If any Restricted Shares are forfeited by the Participant or repurchased by the Company, such Shares may again be granted or awarded hereunder, subject to the limitations of Section 3.1(a). 

3.2    Shares Distributed. Any Shares distributed pursuant to an Award may consist, in whole or in part, of
authorized and unissued Shares, treasury shares (subject to Applicable Laws) or Shares purchased on the open market. Additionally, in the discretion of the Committee, American Depositary Shares in an amount equal to the number of Shares which
otherwise would be distributed pursuant to an Award may be distributed in lieu of Shares in settlement of any Award. If the number of Shares represented by an American Depositary Share is other than on a one-to-one basis, the limitations of Section 3.1 shall be adjusted to reflect the distribution of American Depositary Shares in lieu of Shares. 

ARTICLE 4 
 ELIGIBILITY
AND PARTICIPATION 
 4.1    Eligibility. Persons eligible to participate in this Plan include Employees,
Consultants, and all members of the Board, as determined by the Committee. 
 4.2    Participation. Subject to
the provisions of the Plan, the Committee may, from time to time, select from among all eligible individuals, those to whom Awards shall be granted and shall determine the nature and amount of each Award. No individual shall have any right to be
granted an Award pursuant to this Plan. 
 4.3    Jurisdictions. In order to assure the viability of Awards
granted to Participants employed in various jurisdictions, the Committee may provide for such special terms as it may consider necessary or appropriate to accommodate differences in local law, tax policy, or custom applicable in the jurisdiction in
which the Participant resides or is employed. Moreover, the Committee may approve such supplements to, or amendments, restatements, or alternative versions of, the Plan as it may consider necessary or appropriate for such purposes without thereby
affecting the terms of the Plan as in effect for any other purpose; provided, however, that no such supplements, amendments, restatements, or alternative versions shall increase the share limitations contained in Section 3.1 of the
Plan. Notwithstanding the foregoing, the Committee may not take any actions hereunder, and no Awards shall be granted, that would violate any Applicable Laws.

4.4    Grant of Awards. No Award shall be granted to Participants: 

  
 4. 

 (a)    where the Company has, or reasonably believes there is, material non-public information or inside information that must be disclosed under the applicable laws and regulations, until such information has been published on website of the Company and the relevant stock exchange; or

 (b)    within any black-out period or equivalent period of time restricting
and/or prohibiting the dealing of Shares by Participants before the publication of financial statements of the Company as provided in the rules of the applicable stock exchange; or 

(c)    in any other circumstances where dealings by Participants (including directors of any member of the Group) are
prohibited under any applicable law or regulation or where the requisite approval from any applicable regulatory authorities has not been granted. 

ARTICLE 5 
 RESTRICTED
SHARES 
 5.1    Grant of Restricted Shares. The Committee, at any time and from time to time, may grant
Restricted Shares to Participants as the Committee, in its sole discretion, shall determine. The Committee, in its sole discretion, shall determine the number of Restricted Shares to be granted to each Participant. 

5.2    Restricted Shares Award Agreement. Each Award of Restricted Shares shall be evidenced by an Award Agreement
that shall specify the period of restriction, the number of Restricted Shares granted, and such other terms and conditions as the Committee, in its sole discretion, shall determine. Unless the Committee determines otherwise, Restricted Shares shall
be held by the Company as escrow agent until the restrictions on such Restricted Shares have lapsed. 

5.3    Issuance and Restrictions. Restricted Shares shall be subject to such restrictions on transferability and
other restrictions as the Committee may impose (including, without limitation, limitations on the right to vote Restricted Shares or the right to receive dividends on the Restricted Share). These restrictions may lapse separately or in combination
at such times, pursuant to such circumstances, in such installments, or otherwise, as the Committee determines at the time of the grant of the Award or thereafter. 

5.4    Forfeiture/Repurchase. Except as otherwise determined by the Committee at the time of the grant of the Award
or thereafter, upon termination of employment or service during the applicable restriction period, Restricted Shares that are at that time subject to restrictions shall be forfeited or repurchased in accordance with the Award
Agreement; provided, however, the Committee may (a) provide in any Restricted Share Award Agreement that restrictions or forfeiture and repurchase conditions relating to Restricted Shares will be waived in whole or in part in the
event of termination resulting from specified causes, and (b) in other cases waive in whole or in part restrictions or forfeiture and repurchase conditions relating to Restricted Shares. 

5.5    Certificates for Restricted Shares. Restricted Shares granted pursuant to the Plan may be evidenced in such
manner as the Committee shall determine. If certificates representing Restricted Shares are registered in the name of the Participant, certificates must bear an appropriate legend referring to the terms, conditions, and restrictions applicable to
such Restricted Shares, and the Company may, at its discretion, retain physical possession of the certificate until such time as all applicable restrictions lapse. 

5.6    Removal of Restrictions. Except as otherwise provided in this Article 5 Restricted Shares granted under the
Plan shall be released from escrow as soon as practicable after the last day of the period of restriction. The Committee, in its discretion, may accelerate the time at which any restrictions shall lapse or be removed. After the restrictions have
lapsed, the Participant shall be entitled to have any legend or legends under Section 5.5 removed from his or her Share certificate, and the Shares shall be freely transferable by the Participant, subject to applicable legal restrictions. The
Committee (in its discretion) may establish procedures regarding the release of Shares from escrow and the removal of legends, as necessary or appropriate to minimize administrative burdens on the Company.

  
 5. 

 ARTICLE 6 

RESTRICTED SHARE UNITS 

6.1    Grant of Restricted Share Units. The Committee, at any time and from time to time, may grant Restricted
Share Units to Participants as the Committee, in its sole discretion, shall determine. The Committee, in its sole discretion, shall determine the number of Restricted Share Units to be granted to each Participant. 

6.2    Restricted Share Units Award Agreement. Each Award of Restricted Share Units shall be evidenced by an Award
Agreement that shall specify any vesting conditions, the number of Restricted Share Units granted, and such other terms and conditions as the Committee, in its sole discretion, shall determine. 

6.3    Performance Objectives and Other Terms. The Committee, in its discretion, may set performance objectives or
other vesting criteria which, depending on the extent to which they are met, will determine the number or value of Restricted Share Units that will be paid out to the Participants. 

6.4    Form and Timing of Payment of Restricted Share Units. At the time of grant, the Committee shall specify the
date or dates on which the Restricted Share Units shall become fully vested and nonforfeitable. Upon vesting, the Committee, in its sole discretion, may pay Restricted Share Units in the form of cash, in Shares or in a combination thereof. 

6.5    Forfeiture/Repurchase. Except as otherwise determined by the Committee at the time of the grant of the Award
or thereafter, upon termination of employment or service during the applicable restriction period, Restricted Share Units that are at that time unvested shall be forfeited or repurchased in accordance with the Award Agreement; provided,
however, the Committee may (a) provide in any Restricted Share Unit Award Agreement that restrictions or forfeiture and repurchase conditions relating to Restricted Share Units will be waived in whole or in part in the event of termination
resulting from specified causes, and (b) in other cases waive in whole or in part restrictions or forfeiture and repurchase conditions relating to Restricted Share Units.

ARTICLE 7 
 PROVISIONS
APPLICABLE TO AWARDS 
 7.1    Award Agreement. Awards under the Plan shall be evidenced by Award Agreements
that set forth the terms, conditions and limitations for each Award which may include the term of an Award, the provisions applicable in the event the Participant’s employment or service terminates, and the Company’s authority to
unilaterally or bilaterally amend, modify, suspend, cancel or rescind an Award. 
 7.2    No Transferability; Limited
Exception to Transfer Restrictions. 
 7.2.1    Limits on Transfer. Unless otherwise expressly provided in
(or pursuant to) this Section 7.2, by Applicable Laws and by the Award Agreement, as the same may be amended: 

(a)     all Awards are non-transferable and will not be subject in any manner
to sale, transfer, anticipation, alienation, assignment, pledge, encumbrance or charge; 
 (b)     Awards will be
exercised only by the Participant; and 
 (c)     amounts payable or Shares issuable pursuant to an Award will be
delivered only to (or for the account of), and, in the case of Shares, registered in the name of, the Participant. 

  
 6. 

 In addition, the Shares shall be subject to the restrictions set forth in the applicable
Award Agreement. 
 7.2.2    Further Exceptions to Limits on Transfer. The exercise and transfer restrictions in
Section 7.2.1 will not apply to: 
 (a)    transfers to the Company or a Subsidiary; 

(b)    transfers by gift to “immediate family” as that term is defined in SEC Rule 16a-1(e) promulgated under the Exchange Act; 
 (c)    the designation of a
beneficiary to receive benefits if the Participant dies or, if the Participant has died, transfers to or exercises by the Participant’s beneficiary, or, in the absence of a validly designated beneficiary, transfers by will or the laws of
descent and distribution; 
 (d)    if the Participant has suffered a Disability, permitted transfers or exercises on
behalf of the Participant by the Participant’s duly authorized legal representative; or 
 (e)    transfer to one
or more natural persons who are the Participant’s family members or entities owned and controlled by the Participant and/or the Participant’s family members, including but not limited to trusts or other entities whose beneficiaries or
beneficial owners are the Participant and/or the Participant’s family members, or to such other persons or entities as may be expressly approved by the Committee, pursuant to such conditions and procedures as the Committee may establish. Any
such permitted transfer is subject to the conditions that (i) the Committee receives evidence that the transfer is being made for estate and/or tax planning purposes and on a basis consistent with the Company’s lawful issue of securities
and (ii) the Committee has not in its absolute discretion determined that such evidence is insufficient or otherwise unsatisfactory. 

Notwithstanding anything else in this Section 7.2.2 to the contrary, but subject to compliance with all Applicable Laws, Restricted
Shares and Restricted Share Units will be subject to any and all transfer restrictions under the Code applicable to such Awards or necessary to maintain the intended tax consequences of such Awards. Notwithstanding clause (b) above but subject
to compliance with all Applicable Laws, any contemplated transfer by gift to “immediate family” as referenced in clause (b) above is subject to the condition precedent that the transfer be approved by the Committee in order for it to
be effective. 
 7.3    Beneficiaries. Notwithstanding Section 7.2, a Participant may, in the manner
determined by the Committee, designate a beneficiary to exercise the rights of the Participant and to receive any distribution with respect to any Award upon the Participant’s death. A beneficiary, legal guardian, legal representative, or other
person claiming any rights pursuant to the Plan is subject to all terms and conditions of the Plan and any Award Agreement applicable to the Participant, except to the extent the Plan and Award Agreement otherwise provide, and to any additional
restrictions deemed necessary or appropriate by the Committee. If the Participant is married and resides in a community property state, a designation of a person other than the Participant’s spouse as his or her beneficiary with respect to more
than 50% of the Participant’s interest in the Award shall not be effective without the prior written consent of the Participant’s spouse. If no beneficiary has been designated or survives the Participant, payment shall be made to the
person entitled thereto pursuant to the Participant’s will or the laws of descent and distribution. Subject to the foregoing, a beneficiary designation may be changed or revoked by a Participant at any time provided the change or revocation is
filed with the Committee. 
 7.4    Share Certificates. Notwithstanding anything herein to the contrary, the
Company shall not be required to issue or deliver any certificates evidencing the Shares pursuant to the exercise of any Award, unless and until the Committee has determined, with advice of counsel, that the issuance and delivery of such
certificates is in compliance with all Applicable Laws, regulations of governmental authorities and, if applicable, the requirements of any exchange on which the Shares are listed or traded. 

  
 7. 

 
All Share certificates delivered pursuant to the Plan are subject to any stop-transfer orders and other restrictions as the Committee deems necessary or advisable to comply with all Applicable
Laws, and the rules of any national securities exchange or automated quotation system on which the Shares are listed, quoted, or traded. The Committee may place legends on any Share certificate to reference restrictions applicable to the Shares. In
addition to the terms and conditions provided herein, the Committee may require that a Participant make such reasonable covenants, agreements, and representations as the Committee, in its discretion, deems advisable in order to comply with any such
laws, regulations, or requirements. The Committee shall have the right to require any Participant to comply with any timing or other restrictions with respect to the settlement or exercise of any Award, including a window-period limitation, as may
be imposed in the discretion of the Committee. The Company shall not be required (i) to transfer on its books any Shares that have been sold or otherwise transferred in violation of any of the provisions of the Plan or (ii) to treat as
owner of such Shares or to accord the right to vote or pay dividends to any purchaser or other transferee to whom such Shares shall have been so transferred. 

7.5    Paperless Administration. Subject to Applicable Laws, the Committee may make Awards, provide applicable
disclosure and procedures for exercise of Awards by an internet website or interactive voice response system for the paperless administration of Awards. 

7.6    Foreign Currency. A Participant may be required to provide evidence that any currency used to pay the
exercise price of any Award were acquired and taken out of the jurisdiction in which the Participant resides in accordance with Applicable Laws, including foreign exchange control laws and regulations. In the event the exercise price for an Award is
paid in Chinese Renminbi or other foreign currency, as permitted by the Committee, the amount payable will be determined by conversion from U.S. dollars at the official rate promulgated by the People’s Bank of China for Chinese Renminbi, or for
other foreign currencies, the exchange rate as selected by the Committee on the date of exercise. 
 ARTICLE 8 

CHANGES IN CAPITAL STRUCTURE 

8.1    Adjustments. In the event of any dividend, share split, combination or exchange of Shares, amalgamation,
arrangement or consolidation, spin-off, recapitalization or other distribution (other than normal cash dividends) of Company assets to its shareholders, or any other change affecting the number of Shares or
the price of a Share, the Committee shall make such proportionate adjustments, if any, as the Committee in its discretion may deem appropriate to reflect such change with respect to (a) the aggregate number and type of Shares that may be issued
under the Plan (including, but not limited to, adjustments of the limitations in Section 3.1); (b) the terms and conditions of any outstanding Awards (including, without limitation, any applicable performance targets or criteria with
respect thereto); and (c) the grant or exercise price per Share for any outstanding Awards under the Plan. 

8.2    Corporate Transactions. Except as may otherwise be provided in any Award Agreement or any other written
agreement entered into by and between the Company and a Participant, if the Committee anticipates the occurrence, or upon the occurrence, of a Corporate Transaction, the Committee may, in its sole discretion, provide for (i) any and all Awards
outstanding hereunder to terminate at a specific time in the future and shall give each Participant the right to exercise the vested portion of such Awards during a period of time as the Committee shall determine, or (ii) the purchase of any
Award for an amount of cash equal to the amount that could have been attained upon the exercise of such Award (and, for the avoidance of doubt, if as of such date the Committee determines in good faith that no amount would have been attained upon
the exercise of such Award, then such Award may be terminated by the Company without payment), or (iii) the replacement of such Award with other rights or property selected by the Committee in its sole discretion or the assumption of or
substitution of such Award by the successor or surviving corporation, or a Parent or Subsidiary thereof, with appropriate adjustments as to the number and kind of Shares and prices, or (iv) payment of Award in cash based on the value of Shares
on the date of the Corporate Transaction plus reasonable interest on the Award through the date when such Award would otherwise be vested or have been paid in accordance with its original terms, if necessary to comply with Section 409A of the
Code. 

  
 8. 

 8.3    Outstanding Awards – Other Changes. In the event of
any other change in the capitalization of the Company or corporate change other than those specifically referred to in this Section 8, the Committee may, in its absolute discretion, make such adjustments in the number and class of Shares
subject to Awards outstanding on the date on which such change occurs and in such other terms of each Award as the Committee may consider appropriate to prevent dilution or enlargement of rights. 

8.4    No Other Rights. Except as expressly provided in the Plan, no Participant shall have any rights by reason of
any subdivision or consolidation of Shares of any class, the payment of any dividend, any increase or decrease in the number of Shares of any class or any dissolution, liquidation, merger, or consolidation of the Company or any other corporation.
Except as expressly provided in the Plan or pursuant to action of the Committee under the Plan, no issuance by the Company of Shares of any class, or securities convertible into Shares of any class, shall affect, and no adjustment by reason thereof
shall be made with respect to, the number of Shares subject to an Award or the grant or exercise price of any Award. 
 ARTICLE 9 

ADMINISTRATION 

9.1    Committee. Prior to the Trading Date, the Plan shall be administered by the Board. On and after the Trading
Date, the Plan shall be administered by the compensation committee of the Board, which may delegate its duties and powers in whole or in part to any subcommittee thereof consisting solely of at least two individuals who are intended to qualify as “Non-Employee Directors” within the meaning of Rule 16b-3 under the Act (or any successor rule thereto) and as “independent directors” as defined in the
Listing Rules of the Nasdaq Stock Market or the applicable corporate governance rules of the relevant stock exchange. Any grant or amendment of Awards to any Committee member shall then require an affirmative vote of a majority of the Board members
who are not on the Committee. 
 9.2    Action by the Committee. A majority of the Committee shall constitute a
quorum. The acts of a majority of the members of the Committee present at any meeting at which a quorum is present, and acts approved in writing by a majority of the Committee in lieu of a meeting, shall be deemed the acts of the Committee. Each
member of the Committee is entitled to, in good faith, rely or act upon any report or other information furnished to that member by any officer or other employee of the Company or any Subsidiary, the Company’s independent certified public
accountants, or any executive compensation consultant or other professional retained by the Company to assist in the administration of the Plan. 

9.3    Authority of the Committee. Subject to any specific designation in the Plan, the Committee has the exclusive
power, authority and discretion to: 
 (a)    designate Participants to receive Awards; 

(b)    determine the type or types of Awards to be granted to each Participant; 

(c)    determine the number of Awards to be granted and the number of Shares to which an Award will relate; 

(d)    determine the terms and conditions of any Award granted pursuant to the Plan, including, but not limited to, the
exercise price, grant price, or purchase price, any restrictions or limitations on the Award, any schedule for lapse of forfeiture restrictions or restrictions on the exercisability of an Award, and accelerations or waivers thereof, any provisions
related to non-competition and recapture of gain on an Award, based in each case on such considerations as the Committee in its sole discretion determines; 

  
 9. 

 (e)    determine whether, to what extent, and pursuant to what
circumstances an Award may be settled in, or the exercise price of an Award may be paid in, cash, Shares, other Awards, or other property, or an Award may be canceled, forfeited, or surrendered; 

(f)    prescribe the form of each Award Agreement, which need not be identical for each Participant; 

(g)    decide all other matters that must be determined in connection with an Award; 

(h)    establish, adopt, or revise any rules and regulations as it may deem necessary or advisable to administer the Plan;

 (i)    interpret the terms of, and any matter arising pursuant to, the Plan or any Award Agreement; and 

(j)    make all other decisions and determinations that may be required pursuant to the Plan or as the Committee deems
necessary or advisable to administer the Plan. 
 9.4    Decisions Binding. The Committee’s interpretation
of the Plan, any Awards granted pursuant to the Plan, any Award Agreement and all decisions and determinations by the Committee with respect to the Plan are final, binding, and conclusive on all parties.

ARTICLE 10 
 EFFECTIVE
AND EXPIRATION DATE 
 10.1    Effective Date. This Plan shall become effective on the date on which the Plan
is approved by the shareholders of the Company according to its Memorandum of Association and Articles of Association (the “Effective Date”). 

10.2    Expiration Date. The Plan will expire on, and no Award may be granted pursuant to the Plan after, the tenth
anniversary of the Effective Date. Any Awards that are outstanding on the tenth anniversary of the Effective Date shall remain in force according to the terms of the Plan and the applicable Award Agreement. 

ARTICLE 11 
 AMENDMENT,
MODIFICATION, AND TERMINATION 
 11.1    Amendment, Modification, And Termination. With the approval of the
Board, at any time and from time to time, the Committee may terminate, amend or modify the Plan; provided, however, that (a) to the extent necessary and desirable to comply with Applicable Laws or stock exchange rules, the Company
shall obtain shareholder approval of any Plan amendment in such a manner and to such a degree as required, unless the Company decides to follow home country practice, and (b) unless the Company decides to follow home country practice,
shareholder approval is required for any amendment to the Plan that (i) increases the number of Shares available under the Plan (other than any adjustment as provided by Article 10), (ii) permits the Committee to extend the term of the
Plan, or (iii) results in a material increase in benefits or a change in eligibility requirements. 

11.2    Awards Previously Granted. Except with respect to amendments made pursuant to Section 11.1, no
termination, amendment, or modification of the Plan shall adversely affect in any material way any Award previously granted pursuant to the Plan without the prior written consent of the Participant. 

ARTICLE 12 
 GENERAL
PROVISIONS 
 12.1    Lock-Up Period. A Participant shall agree that,
if so requested by the Company in connection with any registration of the offering of any securities of the Company under the Securities Act 

  
 10. 

 
or any applicable United States state laws, the Participant shall not sell or otherwise transfer any Shares or other securities of the Company during the Market Standoff Period. The Company may
impose stop-transfer instructions with respect to securities subject to the foregoing restrictions until the end of such Market Standoff Period and these restrictions shall be binding on any transferee of such Shares. Notwithstanding the foregoing,
the Market Standoff Period may be extended for up to such number of additional days as is deemed necessary by the Company. 

12.2    No Rights to Awards. No Participant, Employee, or other person shall have any claim to be granted any Award
pursuant to the Plan, and neither the Company nor the Committee is obligated to treat Participants, Employees, and other persons uniformly. 

12.3    No Shareholders Rights. No Award gives the Participant any of the rights of a shareholder of the Company
unless and until Shares are in fact issued to such person in connection with such Award. 
 12.4    Taxes. No
Shares shall be delivered under the Plan to any Participant until such Participant has made arrangements acceptable to the Committee for the satisfaction of any income and employment tax withholding obligations under Applicable Laws. The Company or
any Subsidiary shall have the authority and the right to deduct or withhold, or require a Participant to remit to the Company, an amount sufficient to satisfy all applicable taxes (including the Participant’s payroll tax obligations) required
or permitted by Applicable Laws to be withheld with respect to any taxable event concerning a Participant arising as a result of the Plan. The Committee may in its discretion and in satisfaction of the foregoing requirement allow a Participant to
elect to have the Company withhold Shares otherwise issuable under an Award (or allow the return of Shares) having a Fair Market Value equal to the sums required to be withheld. Notwithstanding any other provision of the Plan, the number of Shares
which may be withheld with respect to the issuance, vesting, exercise or payment of any Award (or which may be repurchased from the Participant of such Award after such Shares were acquired by the Participant from the Company) in order to satisfy
any income and payroll tax liabilities applicable to the Participant with respect to the issuance, vesting, exercise or payment of the Award shall, unless specifically approved by the Committee, be limited to the number of Shares which have a Fair
Market Value on the date of withholding or repurchase equal to the aggregate amount of such liabilities based on the minimum statutory withholding rates for the applicable income and payroll tax purposes that are applicable to such supplemental
taxable income. 
 12.5    No Right to Employment or Services. Nothing in the Plan or any Award Agreement shall
interfere with or limit in any way the right of the Service Recipient to terminate any Participant’s employment or services at any time, nor confer upon any Participant any right to continue in the employment or services of any Service
Recipient. 
 12.6    Unfunded Status of Awards. The Plan is intended to be an “unfunded” plan for
incentive compensation. With respect to any payments not yet made to a Participant pursuant to an Award, nothing contained in the Plan or any Award Agreement shall give the Participant any rights that are greater than those of a general creditor of
the Company or any Subsidiary. 
 12.7    Indemnification. To the extent allowable pursuant to Applicable Laws,
each member of the Committee or of the Board shall be indemnified and held harmless by the Company from any loss, cost, liability, or expense that may be imposed upon or reasonably incurred by such member in connection with or resulting from any
claim, action, suit, or proceeding to which he or she may be a party or in which he or she may be involved by reason of any action or failure to act pursuant to the Plan and against and from any and all amounts paid by him or her in satisfaction of
judgment in such action, suit, or proceeding against him or her; provided he or she gives the Company an opportunity, at its own expense, to handle and defend the same before he or she undertakes to handle and defend it on his or
her own behalf. The foregoing right of indemnification shall not be exclusive of any other rights of indemnification to which such persons may be entitled pursuant to the Company’s Memorandum of Association and Articles of Association, as a
matter of law, or otherwise, or any power that the Company may have to indemnify them or hold them harmless. 

  
 11. 

 12.8    Relationship to other Benefits. No payment pursuant to
the Plan shall be taken into account in determining any benefits pursuant to any pension, retirement, savings, profit sharing, group insurance, welfare or other benefit plan of the Company or any Subsidiary except to the extent otherwise expressly
provided in writing in such other plan or an agreement thereunder. 
 12.9    Expenses. The expenses of
administering the Plan shall be borne by the Company and its Subsidiaries. 
 12.10    Titles and Headings. The
titles and headings of the Sections in the Plan are for convenience of reference only and, in the event of any conflict, the text of the Plan, rather than such titles or headings, shall control. 

12.11    Fractional Shares. No fractional Shares shall be issued and the Committee shall determine, in its
discretion, whether cash shall be given in lieu of fractional Shares or whether such fractional Shares shall be eliminated by rounding up or down as appropriate. 

12.12    Limitations Applicable to Section 16 Persons. Notwithstanding any other provision of
the Plan, the Plan, and any Award granted or awarded to any Participant who is then subject to Section 16 of the Exchange Act, shall be subject to any additional limitations set forth in any applicable exemptive rule under Section 16 of
the Exchange Act (including any amendment to Rule 16b-3 of the Exchange Act) that are requirements for the application of such exemptive rule. To the extent permitted by the Applicable Laws, the Plan and
Awards granted or awarded hereunder shall be deemed amended to the extent necessary to conform to such applicable exemptive rule. 

12.13    Government and Other Regulations. The obligation of the Company to make payment of awards in Shares or
otherwise shall be subject to all Applicable Laws, and to such approvals by government agencies as may be required. The Company shall be under no obligation to register any of the Shares paid pursuant to the Plan under the Securities Act or any
other similar law in any applicable jurisdiction. If the Shares paid pursuant to the Plan may in certain circumstances be exempt from registration pursuant to the Securities Act or other Applicable Laws, the Company may restrict the transfer of such
Shares in such manner as it deems advisable to ensure the availability of any such exemption. 
 12.14    Governing
Law. The Plan and all Award Agreements shall be construed in accordance with and governed by the laws of the Cayman Islands. 

12.15    Section 409A. To the extent that the Committee determines that any Award granted under
the Plan is or may become subject to Section 409A of the Code, the Award Agreement evidencing such Award shall incorporate the terms and conditions required by Section 409A of the Code. To the extent applicable, the Plan and the Award
Agreements shall be interpreted in accordance with Section 409A of the Code and the U.S. Department of Treasury regulations and other interpretative guidance issued thereunder, including without limitation any such regulation or other guidance
that may be issued after the Effective Date. Notwithstanding any provision of the Plan to the contrary, in the event that following the Effective Date the Committee determines that any Award may be subject to Section 409A of the Code and
related Department of Treasury guidance (including such Department of Treasury guidance as may be issued after the Effective Date), the Committee may adopt such amendments to the Plan and the applicable Award agreement or adopt other policies and
procedures (including amendments, policies and procedures with retroactive effect), or take any other actions, that the Committee determines are necessary or appropriate to (a) exempt the Award from Section 409A of the Code and/or preserve
the intended tax treatment of the benefits provided with respect to the Award, or (b) comply with the requirements of Section 409A of the Code and related U.S. Department of Treasury guidance. 

  
 12. 

 12.16    Appendices. The Committee may approve such supplements,
amendments or appendices to the Plan as it may consider necessary or appropriate for purposes of compliance with Applicable Laws or otherwise and such supplements, amendments or appendices shall be considered a part of the Plan; provided,
however, that no such supplements shall increase the share limitation contained in Section 3.1 of the Plan without the approval of the Board. 

  
 13. 

 LEGEND BIOTECH CORPORATION 

RESTRICTED SHARE UNIT AWARD AGREEMENT 
  

 
  

			
	 Name of Grantee:
 Staff ID/PRC
personal ID: [●]
 Address:
	  	 Plan:2020 Restricted Share Plan

Grant: [●] restricted share units

Grant Date: [●]
 Vesting
Commencement Date: [●]
 Expiration Date: [●]

  
  

1.    Grant. Effective on the Grant Date, you have been granted the number of restricted share units (the
“RSU”) designated above, each evidencing the right to receive one (1) ordinary share (“Share”) of Legend Biotech Corporation (the “Company”) upon vesting, in accordance
with the provisions of the 2020 Restricted Share Plan of the Company (the “Plan”) and subject to the restrictions, terms and conditions set forth herein. All terms used but not defined herein shall have the meanings assigned
to them in the Plan. 
 2.    Vesting Schedule. Subject to the terms in this Agreement, the RSUs will vest
in accordance with the following schedule: 
  

			
	Vesting:	  	You will receive a benefit with respect to an RSU only if it vests. The Liquidity Event Requirement and the Service-Based Requirement must be satisfied on or before the applicable Expiration Date specified above in order for an RSU
to vest. An RSU shall actually vest (and therefore become a “Vested RSU”) on the first date upon which both of the Service-Based Requirement and the Liquidity Event Requirement are satisfied with respect to that particular
RSU.
		
	 Liquidity Event

Requirement:
	  	The Liquidity Event Requirement will be satisfied as to any then-outstanding RSUs on the first to occur of: (1) a Corporate Transaction; or (2) the effective date of a registration statement for an initial public offering
of the Company’s Shares.
		
	 Service-Based

Requirement:
	  	 The Service-Based Requirement will be satisfied in installments as to the RSUs as follows: One third (1/3) of the RSUs shall vest on the
first anniversary of the Company Vesting Date that next follows the Vesting Commencement Date, and one- twelfth (1/12th) of the RSUs shall vest on each quarterly Company Vesting Date thereafter, assuming you have not had a Termination of Service (as
defined below) prior to such date. For the avoidance of doubt, once you have had a Termination of Service, no additional RSUs shall be eligible to become Vested RSUs, and any RSUs which are not Vested RSUs as of the date of such Termination of
Service shall be forfeited to the Company and you shall have no further rights with respect to such RSUs.
  

“Company Vesting Date” means each [February 20, May 20, August 20, and November 20].

 3.    Distribution after Vesting. 

(a)    The issuance of shares in respect of the RSUs is intended to comply with Treasury Regulations Section 1.409A-1(b)(4) and will be construed and administered in such a manner. 

  
 14. 

 
Subject to the satisfaction of the Withholding Obligation set forth in Section 9 of this Agreement, in the event an RSU vests, the Company shall issue to you one (1) Share for each RSU
that vests on the applicable vesting date. Each issuance date determined by this paragraph is referred to as an “Original Issuance Date”. 

(b)    If the Original Issuance Date falls on a date that is not a business day, delivery shall instead occur on
the next following business day. In addition, if: 
 (i)    the Original Issuance Date does not occur
(1) during an “open window period” applicable to you, as determined by the Company in accordance with the Company’s then-effective policy on trading in Company securities, or (2) on a date when you are otherwise permitted to
sell Shares on an established stock exchange or stock market (including but not limited to under a previously established written trading plan that meets the requirements of Rule 10b5-1 under the Exchange Act
and was entered into in compliance with the Company’s policies (a “10b5-1 Arrangement”)), and 

(ii)    either (1) a Withholding Obligation does not apply, or (2) the Company decides, prior to the
Original Issuance Date, (A) not to satisfy the Withholding Obligation by withholding Shares from the Shares otherwise due, on the Original Issuance Date, to you under this award, and (B) not to permit you to enter into a “same day
sale” commitment with a broker-dealer pursuant to Section 9 of this Agreement (including but not limited to a commitment under a 10b5-1 Arrangement) and (C) not to permit you to pay your
Withholding Obligation in cash, 
 then the Shares that would otherwise be issued to you on the Original Issuance Date will not be
delivered on such Original Issuance Date and will instead be delivered on the first business day when you are not prohibited from selling Shares in the open public market, but in no event later than December 31 of the calendar year in which the
Original Issuance Date occurs (that is, the last day of your taxable year in which the Original Issuance Date occurs), or, if and only if permitted in a manner that complies with Treasury Regulations
Section 1.409A-1(b)(4), no later than the date that is the 15th day of the third calendar month of the applicable year following the year in which the Shares under this Award are no longer subject to a
“substantial risk of forfeiture” within the meaning of Treasury Regulations Section 1.409A-1(d). 

4.    Register of Members and Share Certificate. The unvested portion of the RSUs will not be registered on
the Company’s Register of Members. With respect to any vested portion of the RSUs that will be distributed in whole Shares, the Company will issue the corresponding number of Shares to you and enter the your name into the Register of Members
subject to Section 6. After the Company has entered your name into the Register of Members with respect to any Shares issued to you, it may, but is not obligated to, issue one or more share certificates, registered in your name and bearing such
legend as the Company deems necessary and appropriate, evidencing such Shares issued. 
 5.    Termination of
Service. In the event your employment or service for the Company or any of its subsidiaries or affiliates to which you are providing services or by which you are employed as of the Grant Date (each a “Service Recipient”)
is terminated for any reason, whether such termination is occasioned by you, by the Service Recipient, with or without cause, or by mutual agreement (“Termination of Service”), your right to any unvested portion of the RSUs
will terminate, and such unvested portion of the RSUs will cease to vest, as of the earlier of: (i) the date that you give or are provided with written notice of such termination, or (ii) if you are an employee of a Service Recipient, the
date from which you are no longer actively employed and physically present on the premises of the Service Recipient, regardless of any notice period or period of pay in lieu of such notice required under any applicable statute or the common law.

 6.    Additional Conditions to Issuance of Shares. The Company shall not be required to issue Shares
hereunder prior to fulfillment of all the following conditions: (a) the listing of such Shares or 

  
 15. 

 
depositary shares representing such Shares on a stock exchange on which such class of stock is then listed; (b) the completion of any registration or other qualification of such Shares or
depositary shares representing such Shares under any U.S. state or federal law or under the rulings or regulations of the U.S. Securities and Exchange Commission or any other governmental regulatory body, which the Committee shall, in its absolute
discretion, deem necessary or advisable; (c) the obtaining of any approval or other clearance from any U.S., Cayman Islands or Chinese governmental agency, which the Committee shall, in its absolute discretion, determine to be necessary or
advisable; and (d) the lapse of such reasonable period of time following any vesting date as the Committee may establish from time to time for reasons of administrative convenience. Furthermore, the Company will not be required to issue Shares
hereunder prior to the expiration of the lock-up period in connection with the Company’s initial public offering. In addition, you agree that the Company may also impose other conditions or administrative
measures to ensure or facilitate the compliance with any applicable law to which you or the Company is subject. 

7.    Limited Rights. Neither you nor any person claiming under or through you will have any of the rights
or privileges of a shareholder of the Company in respect of any Shares deliverable hereunder unless and until such Shares have been issued and registered on the Register of Members of the Company under your name. Subject to Section 8 below,
after such issuance and registration, you will have all the rights of a shareholder of the Company with respect to voting of such Shares and receipt of dividends and distributions on such Shares. 

8.    Award Is Not Transferable. Except pursuant to the written consent of the Committee, this award and the
rights and privileges conferred hereby shall not be transferred, assigned or otherwise disposed of in any way (whether by operation of law or otherwise). Upon any attempt to transfer, assign or otherwise dispose of this award or any right or
privilege conferred hereby, this award and the rights and privileges conferred hereby immediately will become null and void. 
 In the event
of granting written consents for any transfer, the Committee will have the fullest discretion permitted by applicable law in deciding the extent to which, and stipulating terms and conditions under which, such transfer of this award may be allowed
(including, but not limited to, the transfer of part or all of the RSUs). In the event of a transfer of part or all of the RSUs held by you as consented to by the Committee, you hereby acknowledge and agree that you have the obligation to ensure
that the transferee will be subject to and comply with the same terms, conditions, requirements and restrictions imposed on you by the Company in connection with the RSUs granted hereunder. 

9.    Withholding Obligation. On each vesting date, and on or before the time you receive a distribution of
the Shares in respect of your RSUs, and at any other time as reasonably requested by the Company in accordance with applicable tax laws, you hereby authorize any required withholding from the Shares issuable to you and/or otherwise agree to make
adequate provision, including in cash, for any sums required to satisfy the federal, state, local and foreign tax withholding obligations of the Company or any Affiliate that arise in connection with your Award (the “Withholding
Obligation”). By accepting this Award, you acknowledge and agree that the Company may, in its sole discretion, satisfy all or any portion of the Withholding Obligation relating to your RSUs by any of the following means or by a
combination of such means: (i) causing you to pay any portion of the Withholding Obligation in cash; (ii) withholding from any compensation otherwise payable to you by the Company; (iii) withholding Shares from the Shares issued or
otherwise issuable to you in connection with the Award with a Fair Market Value (measured as of the date Shares are issued pursuant to Section 3) equal to the amount of such Withholding Obligation; provided, however, that the number of such
Shares so withheld will not exceed the amount necessary to satisfy the Withholding Obligation using the maximum statutory withholding rates for federal, state, local and foreign tax purposes, including payroll taxes, that are applicable to
supplemental taxable income; and provided, further, that to the extent necessary to qualify for an exemption from application of Section 16(b) of the Exchange Act, if applicable, such share withholding procedure will be subject to the express
prior approval of the Board or the Company’s Compensation Committee; and/or (iv) permitting or requiring you to enter into a “same day sale” commitment, if applicable, with a broker-dealer that is a member of the Financial
Industry Regulatory Authority (a “FINRA Dealer”), pursuant to this authorization and without further consent, whereby you irrevocably elect to sell a portion of the shares to be delivered

  
 16. 

 
in connection with your Restricted Stock Units to satisfy the Withholding Obligation and whereby the FINRA Dealer irrevocably commits to forward the proceeds necessary to satisfy the Withholding
Obligation directly to the Company and/or its Affiliates. Unless the Withholding Obligation is satisfied, the Company shall have no obligation to deliver to you any Shares or any other consideration pursuant to this Award. In the event the
Withholding Obligation arises prior to the delivery to you of Shares or it is determined after the delivery of Shares to you that the amount of the Withholding Obligation was greater than the amount withheld by the Company, you agree to indemnify
and hold the Company harmless from any failure by the Company to withhold the proper amount. 

10.    Personal Data. You acknowledge and consent to the collection, use, processing and transfer of
personal data as described in this paragraph. The Company, its affiliates and your employer hold certain personal information, including your name, home address and telephone number, date of birth, identification number, salary, nationality, job
title, any shares awarded, cancelled, purchased, vested, unvested or outstanding in your favor, for the purpose of managing and administering the Plan (the “Data”). The Company and its affiliates will transfer Data to any
third parties assisting the Company in the implementation, administration and management of the Plan. These recipients may be located in China or elsewhere such as the European Economic Area or the United States. You authorize them to receive,
possess, use, retain and transfer the Data, in electronic or other forms, for the purposes of implementing, administering and managing your participation in the Plan, including any requisite transfer of such Data as may be required for the
administration of the Plan and/or the subsequent holding of shares on your behalf to a broker or other third party with whom you may elect to deposit any shares acquired pursuant to the Plan. You may, at any time, review the Data, require any
necessary amendments thereto or withdraw the consent herein in writing by contacting the Company; however, withdrawing the consent may affect your ability to participate in the Plan. 

11.    Voluntary Participation. Your participation in the Plan is voluntary. The value of the RSUs is an
extraordinary item of compensation outside the scope of your employment contract, if any. As such, the RSUs are not part of normal or expected compensation for purposes of calculating any severance, resignation, redundancy, end of service payments,
bonuses, long-service awards, pensions or retirement benefits or similar payments unless specifically and otherwise provided. Rather, the awarding of the RSUs under the Plan represents a mere investment opportunity. 

12.    Adjustments. You hereby acknowledge and agree that, in the event of any dividend, share split,
combination or exchange of Shares, amalgamation, arrangement or consolidation, spin-off, recapitalization or other distribution (other than normal cash dividends) of Company assets to its shareholders, or any
other change affecting the number of Shares or the price of a Share, the Committee shall make such proportionate adjustments, if any, as the Committee in its discretion may deem appropriate to reflect such change with respect to (a) the
aggregate number and type of Shares that may be issued under the Plan (including, but not limited to adjustments of the limitations in Section 3.1 of the Plan); (b) the terms and conditions of any outstanding Awards (including, without
limitation, any applicable performance targets or criteria with respect thereto); and (c) the grant or exercise price per Share for any outstanding Awards under the Plan. 

13.    Discretionary Plan. This RSU award is granted under and governed by the terms and conditions of the
Plan. You acknowledge and agree that the Plan is discretionary in nature and may be amended, cancelled or terminated by the Company, in its sole discretion, at any time. The grant of this RSU award under the Plan is a
one-time benefit and does not create any contractual or other right to receive an award of RSUs or benefits in lieu of the award in the future. Future awards of RSUs, if any, will be at the sole discretion of
the Company, including, but not limited to, the timing of the award, the number of RSUs awarded, and vesting provisions. By execution of this Agreement, you consent to the provisions of the Plan and this Agreement. 

14.    Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the
Cayman Islands. 
 (Signature page to follow) 

  
 17. 

 
	
	 LEGEND BIOTECH CORPORATION

	
	  

	 Name:

	 Title:

  

	
	 ACKNOWLEDGED AND AGREED BY:

	 (Grantee)

	
	  

	 Name:EX-10.8

 Exhibit 10.8 

Execution Version 

COLLABORATIVE RESEARCH AND LICENSE AGREEMENT 
  

 
 BY AND
BETWEEN 
 NOILE-IMMUNE BIOTECH, INC. 

AND 

LEGEND BIOTECH USA, INC. 

April 27, 2020 
 [***] = Certain
information contained in this document, marked by brackets, has been omitted because it is both not material and would be competitively harmful if publicly disclosed. 

 Confidential 
  

 Table of Contents 
  

							
	 1.
	  	DEFINITIONS	  	 	1	 
	 2.
	  	GOVERNANCE	  	 	11	 
	 3.
	  	TARGET NOMINATION, SELECTION AND SUBSTITUTE	  	 	12	 
	 4.
	  	RESEARCH AND DEVELOPMENT (R&D) PLAN	  	 	14	 
	 5.
	  	DEVELOPMENTS AND REGULATORY APPROVAL	  	 	16	 
	 6.
	  	COMMERCIALIZATION	  	 	17	 
	 7.
	  	GRANT OF LICENSE	  	 	18	 
	 8.
	  	TECHNOLOGY TRANSFER	  	 	19	 
	 9.
	  	CONSIDERATION	  	 	20	 
	 10.
	  	PAYMENTS BY LEGEND	  	 	21	 
	 11.
	  	INTELLECTUAL PROPERTY AND PATENT INFRINGEMENT	  	 	23	 
	 12.
	  	CONFIDENTIAL INFORMATION	  	 	25	 
	 13.
	  	PUBLICATION	  	 	27	 
	 14.
	  	REPRESENTATIONS AND WARRANTIES	  	 	27	 
	 15.
	  	DISCLAIMER AND LIMITATION OF LIABILITY	  	 	29	 
	 16.
	  	INDEMNIFICATION	  	 	30	 
	 17.
	  	TERM AND TERMINATION	  	 	31	 
	 18.
	  	MISCELLANEOUS PROVISIONS	  	 	33	 

 EXHIBITS 
  

			
	     EXHIBIT A
	  	 Noile Patents

	     EXHIBIT B
	  	 Noile’s Bank Account

  
 - i - 

 Confidential 
  

 COLLABORATIVE RESEARCH AND LICENSE AGREEMENT 

THIS COLLABORATIVE RESEARCH AND LICENSE AGREEMENT (this “Agreement”) is made as of April __, 2020 (the
“Effective Date”) by and between Noile-Immune Biotech, Inc., a Japanese corporation having its principal place of business at 2-12-10
Shiba-Daimon, Minato-ku, Tokyo 105-0012, Japan (“Noile”), and Legend Biotech USA, Inc., a company incorporated under the laws of New York having
its principal place of business at 10 Knightsbridge Road, Piscataway, NJ 08854, USA (“Legend”). Noile and Legend are sometimes referred to herein individually as a “Party” and collectively as the
“Parties.” 
 RECITALS 

WHEREAS, Noile, a biopharmaceutical company focused on the development of novel cancer immunotherapy products, is developing
proprietary Products; 
 WHEREAS, Legend is a pharmaceutical company focused on discovering and developing cutting-edge cell-based
therapies with the ultimate goal of changing the way life-threatening diseases are treated; 
 WHEREAS, Noile and Legend desire to
perform certain research works and are willing to enter into Initial Research to apply their collective expertise, capabilities and resources to develop Products and novel CAR-T platforms based on technology
owned or controlled by Noile; and 
 WHEREAS, in connection with such Initial Research, Legend wishes to be granted, and Noile
desires to grant, certain license and option rights under certain patents, patent applications, know-how, and other proprietary information related to Noile Platform, Licensed Compounds and Licensed Products;

 NOW, THEREFORE, in consideration of the premises and mutual covenants herein contained, Noile and Legend agree as follows: 

1. DEFINITIONS 
 As used in this
Agreement, capitalized terms have the meanings given them below or elsewhere in this Agreement: 
 1.1. “7x19 CAR-T” means Noile’s proprietary CAR-T technology, including a construct expressing a CAR directed against a given target, the cytokine IL-7, and the chemokine CCL19. 
 1.2. “Affiliate” means, with respect to a Party, any
entity that, directly or indirectly, controls, is controlled by or is under common control with such Party for so long as such control exists. For purposes of this definition, an entity has “control” of another entity if it has the direct
or indirect ability or power to direct, or cause the direction of management policies of such other entity or otherwise direct the affairs of such other entity, whether through ownership of [***] fifty percent (50%) of the voting securities of such
other entity, by contract or otherwise. 

  
 - 1 - 

 Confidential 
  

 1.3. “Alliance Manager” means an alliance leader appointed by each Party to
coordinate and facilitate the communication, interaction and cooperation of the Parties pursuant to this Agreement. Detailed information of the Alliance Manager is described in Section 2.4. 

1.4. “Applicable Laws” mean any laws, regulations, guidelines, or standards applicable to the conduct of the collaboration or
other activities under this Agreement. 
 1.5. “Calendar Half Year” means a period of six (6) consecutive calendar
months ending on June 30 and December 31, respectively; provided that (a) the first Calendar Half Year of the term shall extend from the Effective Date to the end of the next complete Calendar Half Year thereafter; and
(b) the last Calendar Half Year of the term shall end upon the expiration or termination of this Agreement. 
 1.6. “Calendar
Quarter” means a period of three (3) consecutive calendar months ending on March 31, June 30, September 30 and December 31, respectively; provided that (a) the first Calendar Quarter of the term shall
extend from the Effective Date to the end of the subsequent complete Calendar Quarter thereafter; and (b) the last Calendar Quarter of the term shall end upon the expiration or termination of this Agreement. 

1.7. “CAR” means a chimeric antigen receptor. 

1.8. “CAR-T” means engineered T-cells that
express a CAR on their cell membrane which have [***]. 
 1.9. “Clinical Trial” means any human clinical study or trial of
the Licensed Product in the Territory. 
 1.10. “Combination Product” means a Licensed Product containing a Licensed
Compound as well as at least one other active pharmaceutical ingredient. For the avoidance of doubt, all Combination Products are also Licensed Products. 

1.11. “Combinational Target” means any Target having a specific combination of [***] therein. 

1.12. “Commercial License” has the meaning as set forth in Section 7.3. 

1.13. “Commercialization” means, with respect to a Licensed Product, any and all activities (whether before or after
Regulatory Approval) directed to the marketing, promotion and sale of such Licensed Product after Regulatory Approval for commercial sale has been obtained, including pre-launch and post-launch marketing,
promoting, marketing research, distributing, offering to commercially sell and commercially selling such Licensed Product, importing, exporting or transporting such Licensed Product for commercial sale, medical education activities with respect to
such Licensed Product, conducting Clinical Trials that are not required to obtain or maintain Regulatory Approval for such Licensed Product for an indication, which may include epidemiological studies, modeling and pharmacoeconomic studies,
post-marketing surveillance studies, investigator sponsored studies and health economics studies and regulatory affairs (including interacting with Regulatory Authorities) with respect to the foregoing. When used as a verb, “Commercialize”
means to engage in Commercialization activities. 

  
 - 2 - 

 Confidential 
  

 1.14. “Commercially Reasonable Efforts” means, with respect to a Party and a
product owned by it or to which it otherwise has rights, the efforts which are reasonable for [***] in accordance with its business, legal, medical, and scientific judgment, and the efforts and resources that it would use for a [***], taking into
account the [***]. For the clarity, “Commercially Reasonable Efforts” shall be evaluated or determined on a country-by-country and Product-by-Product basis, as
applicable. 
 1.15. “Confidential Information” means all information pertinent to this Agreement, Initial Research,
information in project proposals and project charters, and activities made with regard to this Agreement, in whatever form, oral, written, electronic or otherwise, that is (a) marked or designated as confidential, (b) defined as
confidential in this Agreement, or (c) of the type that would generally be regarded as confidential or proprietary in the scientific, academic or healthcare communities, and in each case, (a)–(c), that is disclosed or provided by or on
behalf of a disclosing Party, including its Affiliates, to a receiving Party, including its Affiliates or to any of the receiving Party’s or its Affiliates’ directors, officers, faculty, employees, contractors, consultants, advisors or
agents pursuant to or in connection with this Agreement. The contents of this Agreement shall also be treated as the Confidential Information of each Party under this Agreement. Notwithstanding the foregoing, Confidential Information shall not
include (i) information that is or becomes generally available to the public other than as a result of any action or inaction by the receiving Party, (ii) information that was received by or becomes available to the receiving Party on a non-confidential basis from a source other than the disclosing Party; provided however, that the source of such information was not bound by a confidentiality agreement with, or other contractual, legal or fiduciary
obligation of confidentiality to, any person or entity with respect to such information, or (iii) information that was known prior to the disclosure or is developed independently by or on behalf of the receiving Party or any of its Affiliates
without reference to or use of the information supplied by the disclosing Party under this Agreement. Notwithstanding anything herein to the contrary, any Work Results shall be the Confidential Information of the Party that owns such Work Results in
accordance with Section 11.1. 
 1.16. “Control” or “Controlled” means, with respect to any
Intellectual Property right and a Party, possession by such Party or an Affiliate of such Party of the ability to grant the right to access or use, or to grant a license or a sublicense to, such Intellectual Property right as provided for herein
without violating the terms of any agreement or other arrangement with any Third Party. 
 1.17. “Data Protection” means
the situation where any regulation, law or statute of a government authority: 
  

	 	(a)	 exists in any country in the Territory; and 

  
 - 3 - 

 Confidential 
  

	 	(b)	 directly or indirectly protects (regardless of whether any Valid Claim exists in that country), the exclusive
sale of any Licensed Product from the sale in that country of a Third Party’s pharmaceutical product containing the same active pharmaceutical ingredient that is contained in such Licensed Product. 

1.18. “Data Protection Period” means, on a
country-by-country and Licensed Product-by-Licensed Product basis, the period in which
Data Protection with respect to a Licensed Product exists in such country. For the avoidance of doubt, Data Protection Period includes “Re-examination Period” (saishinsa kikan) in Japan. 

1.19. “Development” means all research, non-clinical and clinical drug development
activities, including toxicology, pharmacology, and other non-clinical efforts, statistical analysis, formulation development, delivery system development, the performance of any such research or Clinical
Trials, including the manufacturing of Licensed Compounds or Licensed Products for use in Clinical Trials, or other activities reasonably necessary in order to obtain, but not maintain, Regulatory Approval of Licensed Compounds or Licensed Products
in the Territory. “Development” shall exclude all Commercialization activities. When used as a verb, “Develop” means to engage in Development activities. 

1.20. “Disputes” has the meaning as set forth in Section 18.2(a). 

1.21. “Excluded Target” has the meaning as set forth in Section 3.3. 

1.22. “FDA” means the U.S. Food and Drug Administration, or any successor agency thereto. 

1.23. “Field” means all indications and uses, including the diagnosis, prognosis, prevention, and treatment of human diseases
and human conditions. 
 1.24. “First Commercial Sale” means, on a country-by-country basis, the first sale of a Licensed Product under this Agreement by Legend, its Affiliates or Sublicensees to an end user or prescriber for use, consumption or resale of the Licensed
Product in a country in the Territory where Regulatory Approval of the Licensed Product has been obtained and where the sale results in a recordable Net Sale. Sale of a Licensed Product under this Agreement by Legend to an Affiliate of Legend or a
Sublicensee of Legend shall not constitute a First Commercial Sale unless such Affiliate or such Sublicensee is the end user of such Licensed Product and such sale results in a Net Sale. Also, sale of a Licensed Product under this Agreement by
Legend, its Affiliates or Sublicensees in a jurisdiction where Regulatory Approval for that Licensed Product has not yet been attained shall not constitute a First Commercial Sale under this Agreement. 

1.25. “Force Majeure” has the meaning as set forth in Section 18.6. 

1.26. “Generic/Biosimilar Competition Period” means a period during the portion of the applicable Royalty Term in a
particular country where there are one or more products being sold in such country that are Generic/Biosimilar with respect to such Licensed Product, and where such sales of such product(s), [***] of the sales of the Licensed Product. As used
herein, “Generic/Biosimilar” means any drug or biological product that [***] under the FD&C Act or the PHS Act and related rules and regulations, or the corresponding or similar laws, rules and regulations of any other
jurisdiction and where such drug or biological product obtains 

  
 - 4 - 

 Confidential 
  

 
Regulatory Approval based on[***] to a Licensed Product hereunder. For purposes of this definition, (a) “FD&C Act” means the United States Federal Food, Drug and Cosmetic
Act, as amended, and the regulations promulgated thereunder from time to time and (b) “PHS Act” means the Public Health Services Act, as amended, and the regulations promulgated thereunder from time to time. 

1.27. “GLP” means all applicable current Good Laboratory Practice standards for laboratory activities for pharmaceuticals, as
set forth in the FDA’s Good Laboratory Practice regulations as defined in 21 C.F.R. Part 58 and/or the Good Laboratory Practice principles of the Organization for Economic Co-Operation and Development,
and such standards of good laboratory practice as are required by the European Union and other organizations and governmental agencies in countries in which the relevant activity under this Agreement is being performed. 

1.28. “GMP” means all current Good Manufacturing Practices applicable to biopharmaceuticals in the US and/or in the European
Union, as are in effect from time to time during the effective term of this Agreement and in each case as applicable to the activities being carried out under this Agreement. 

1.29. “GxP” means any of the following as applicable to this Agreement: GLP and GMP. 

1.30. “IND” means (a) an Investigational New Drug application as defined in the Federal Food, Drug, and Cosmetic Act, as
amended, and applicable regulations promulgated thereunder by the FDA, (b) a clinical trial authorization application for a product filed with a Regulatory Authority in any other regulatory jurisdiction outside the U.S., the filing of which (in
the case of (a) or (b)) is necessary to commence or conduct clinical testing of a pharmaceutical product in humans in such jurisdiction, or (c) documentation issued by a Regulatory Authority that permits the conduct of clinical testing of
a pharmaceutical product in humans in such jurisdiction. 
 1.31. “Indemnitee” has the meaning as set forth in
Section 16.3. 
 1.32. “Indemnitor” has the meaning as set forth in Section 16.3. 

1.33. “Initial Payment” means the initial payment paid upon each Legend Selected Target having been formally designated in
accordance with Section 3.4, which detail is described in Section 9.1. 
 1.34. “Initial Research” means the
research activities to be performed mainly within the Initial Research Term on a Target-by-Target or
Product-by-Product basis, but sometimes performed before the IND at the latest for each Product generated from a Licensed Target. 

1.35. “Initial Research Term” means the period of [***] following the Effective Date, as may be modified as described in
Section 3.4, during which any of the Legend Selected Targets shall be selected and nominated. 

  
 - 5 - 

 Confidential 
  

 1.36. “Intellectual Property” means the following subsisting throughout the
world (a) patents, patent applications, utility models, design registrations and certificates of invention and other governmental grants for the protection of inventions or industrial designs (including all related continuations, continuations-in-part, divisionals, reissues and reexaminations); (b) copyrights, designs, data and database rights and registrations and applications for registration
thereof; (c) inventions, invention disclosures, statutory invention registrations, whether patentable or nonpatentable, whether copyrightable or noncopyrightable and whether or not reduced to practice; (d) trade secret and proprietary know-how; and (e) any other proprietary rights relating to any of the foregoing (including remedies against infringement thereof and rights of protection of interest therein under the laws of all
jurisdictions). 
 1.37. “Legend Personnel” means directors, officers, employees, contractors and subcontractors of Legend.

 1.38. “Legend Selected Target” has the meaning as set forth in Section 3.4. 

1.39. “Licensed Compound” means any construct that is designed to secrete both cytokine
IL-7 and chemokine CCL19 in a CAR-T or TCR-T that binds to a Legend Selected Target or a Licensed Target. 

1.40. “Licensed Know-How” means all technology, data, information, know-how, trade secrets, materials (including biological materials), compounds and inventions that are necessary or reasonably useful for the Development, manufacture and/or Commercialization of Licensed Compounds
and/or Licensed Products in the Field in the Territory that are proprietary to and owned or Controlled by Noile as of the Effective Date. Licensed Know-How includes all chemical, structural, manufacturing
process, biological, target, pharmacological, toxicological, clinical, assay and other methods of screening, structure activity relationship information or other information that relates to any Legend Selected Target, Licensed Target, Licensed
Compound and/or Licensed Product (including in each case its composition, formulation, or method of use, manufacture, preparation or administration). Noile shall, to the extent reasonably practicable, notify Legend [***] in relation to those
Licensed Know-How which [***] to the Development, manufacture and/or Commercialization by Legend of Licensed Product in the Field. In such case, [***], the Parties shall discuss in good faith
(i) regarding [***], and (ii) regarding the terms and conditions for [***]. For the avoidance of doubt, nothing under this Section 1.40 shall require Noile to breach its confidentiality obligations to any third party under non-disclosure agreements or other similar agreements. To the extent that [***]. 

  
 - 6 - 

 Confidential 
  

 1.41. “Licensed Patents” mean any and all patents and patent applications
(including all claims and the entire scope of claims therein) owned or Controlled by Noile, as of the Effective Date, as listed in Exhibit A, and all divisionals, continuations, substitutions, continuations-in-part, re-examinations, reissues, additions, renewals, extensions, registrations, supplemental protections, complementary certificates, and the like
thereof, and all foreign counterparts thereof, that are owned or Controlled by Noile as of the Effective Date claiming a Legend Selected Target, a Licensed Target, a Licensed Compound and/or a Licensed Product (including in each case its
composition, formulation, combination, product by process, or method of use, manufacture, preparation or administration), or otherwise claiming inventions that are necessary or reasonably useful for the Development, manufacture and/or
Commercialization of Licensed Compounds and/or Licensed Products in the Field in the Territory. 
 1.42. “Licensed Product”
means any pharmaceutical preparation containing the Licensed Compound, alone or in combination with one or more additional active ingredients, for sale by prescription,
over-the-counter, or any other method. For clarification, a Licensed Product shall be [***]. 

1.43. “Licensed Target” means the Legend Selected Target which becomes a Target for Developing and Commercializing Licensed
Compounds and/or Licensed Products under the Commercial License, as designated by Legend in accordance with Section 3.1(b). The total number of Licensed Targets hereunder shall not be more than two (2). 

1.44. “List” has the meaning set forth in Section 3.3. 

1.45. “Loss” or “Losses” has the meaning as set forth in Section 16.1. 

1.46. “MAAs” or “Marketing Approval Application” means a BLA, sBLA, NDA, sNDA and any equivalent thereof in
the USA or any other country or jurisdiction. As used herein: “BLA” means a Biologics License Application and amendments thereto filed pursuant to the requirements of the FDA, as defined in 21 C.F.R. § 600 et seq., for FDA approval of
a Product and “sBLA” means a supplemental BLA; and “NDA” means a New Drug Application and amendments thereto filed pursuant to the requirements of the FDA, as defined in 21 C.F.R. § 314 et seq., for FDA approval of a Product
and “sNDA” means a supplemental NDA. 
 1.47. “Major Country” means each country of USA, a Major European
Country, [***]. 
 1.48. “Major European Country” means [***]. 

1.49. “Milestone Payment” means each milestone payment as described in Section 9.2. 

1.50. “Net Sales” 

(i) Licensed Products other than Combination Products 

  
 - 7 - 

 Confidential 
  

 The term “Net Sales” of a Licensed Product (other than a Combination Product) shall
mean the gross invoice amount (not including value added taxes, sales taxes, or similar taxes) of the Licensed Product sold by Legend, its Affiliates or Sublicensees to the first Third Party after deducting the following, if not previously deducted,
from the amount invoiced or received: 
  

	 	a)	 trade and quantity discounts other than early payment cash discounts; 

 

	 	b)	 returns, rebates, chargebacks, and other allowances; 

 

	 	c)	 retroactive price reductions that are actually allowed or granted; 

 

	 	d)	 [***]; and 

  

	 	e)	 [***]. 

Net Sales shall be calculated on a country-by-country and
Licensed Product-by-Licensed Product basis, so that a separate figure for Net Sales is calculated for each Licensed Product in each country in which it is sold. 

For the purpose of calculating the Net Sales of a Licensed Product (other than a Combination Product), any deductions shall be limited to
those applied under Legend’s standard operating procedures. 
 Sales of Licensed Products (other than Combination Products) between
Legend and Legend’s Affiliates and/or Sublicensees shall be excluded from the computation of Net Sales. 
 Notwithstanding any
deductions referred to in a) to e) above, the Net Sales of a Licensed Product (other than a Combination Product) shall [***]. 
 (ii)
Combination Products (where an invoice price for a Licensed Product containing the Licensed Compound sold as a single agent exists) 
 In
the case of a Combination Product (where an invoice price for a Licensed Product containing the Licensed Compound sold as a single agent exists), Net Sales shall be calculated on the basis of the gross invoice amount of a Licensed Product [***].

 The deductions referred to in a) to e) of part (i) above shall be calculated and deducted from the gross invoice amount of the
Combination Product on the basis of a Licensed Product [***]. 
 For the purpose of calculating Net Sales of a Combination Product, any
deductions shall be limited to those applied under Legend’s standard operating procedures. 
 Sales of Combination Products between
Legend and Legend’s Affiliates and/or Sublicensees shall be excluded from the computation of Net Sales. 
 Notwithstanding any
deductions referred to in a) to e) of part (i) above (as adjusted according to this part (ii)), the Net Sales of a Combination Product shall [***]. 

(iii) Combination Products (where an invoice price for the Licensed Product sold as a single agent does not exist) 

If only Combination Products are sold in a particular country, an adjusted gross invoice amount for the Combination Products sold within that
country shall be calculated [***]. 

  
 - 8 - 

 Confidential 
  

 1.51. “Noile Platform” means Noile’s 7x19 CAR-T platform that can be applied to CAR-T/TCR-T [***] cell therapy. 

1.52. “Noile Research” has the meaning as set forth in Section 3.3. 

1.53. “Noile Technology” means technology created or developed by Noile outside the performance of this Agreement, including
without limitation the Noile Platform, Licensed Know-How and Licensed Patents. In principle, Noile Technology as used under this Agreement shall refer to those technology as of the Effective Date; provided,
however, that Noile shall, to the extent practicable, notify Legend [***] with respect to advances and/or improvements in relation to those Noile Technology which [***] to the Development, manufacture and/or Commercialization by Legend of Licensed
Compounds and/or Licensed Products in the Field, based on which the Parties shall discuss in good faith regarding potential addition of such advances and/or improvements to the scope of the Research License and/or the Commercial License and the
terms and conditions for such addition, including without limitation [***]. For the avoidance of doubt, nothing under this Section 1.53 shall require Noile to breach its confidentiality obligations to any third party under non-disclosure agreements or other similar agreements. 
 1.54. “Phase II Clinical Trial”
means a Clinical Trial of a Licensed Product with the endpoint of evaluating its effectiveness for a particular indication or indications in one or more specified doses or its short-term tolerance and safety, as well as its pharmacokinetic and
pharmacodynamic information in patients with the indications under study. 
 1.55. “Priority Date” has the meaning as set
forth in Section 3.2. 
 1.56. “Product” means a pharmaceutical or biologic product containing CAR-T or TCR-T directed against a particular Target. 
 1.57.
“Noile Materials” has the meaning as set forth in Section 8.2. 
 1.58. “Project Team” means a team
of the personnel involved in managing and/or executing the Initial Research. The Project Team may be established on a project-by-project basis, each of such projects
shall be identified in the Research and Development Plan. 
 1.59. “Regulatory Approval” means any approval (including
supplement, amendment, pre- and post-approval, pricing approval and reimbursement approval), licenses, registrations or authorizations of any national, regional, state or local Regulatory Authority,
department, bureau, commission, council or other government authority, that is necessary for the commercialization of Licensed Product under this Agreement. 

  
 - 9 - 

 Confidential 
  

 1.60. “Regulatory Authority” means the FDA or any other regulatory authority
or body with regulation or governance over the performance of any part of the activities under this Agreement.  

1.61. “Research License” has the meaning as set forth in Section 7.1. 

1.62. “Research and Development Plan” means a written research and development plan of the Development ending in Regulatory
Approval of Licensed Products Targeting a Legend Selected Target describing (i) the collaborative research activities to be pursued by the Parties under this Agreement, (ii) allocation of responsibilities or roles of each Party,
(iii) the anticipated timeline, (iv) [***], in each case with respect to the Legend Selected Target and development activities related to Licensed Compounds and Licensed Products, as amended from time to time [***]. 

1.63. “Royalty Term” means, on a
country-by-country, Licensed Product-by-Licensed Product and Licensed Target-by-Licensed Target basis, the period commencing on the First Commercial Sale of a Licensed Product in a country in the Territory and ending upon the later of:
(i) expiration of the Data Protection Period with respect to such Licensed Product in such country or (ii) expiration of the last to expire Valid Claim covering such Licensed Product in such country or (iii) the tenth (10th) anniversary of
the First Commercial Sale of the first Licensed Product Targeting such Licensed Target in such country. 
 1.64. “SAE”
means a serious adverse event, as defined and revised by the U.S. FDA, resulting from any Clinical Trial or administration of a Product. 

1.65. “Sublicensee” means a Third Party or Affiliate of Legend which has been granted a sublicense under the Commercial
License by Legend [***]. 
 1.66. “Substitute Option Right” has the meaning as set forth in Section 3.6(a). 

1.67. “Substituted Target” has the meaning as set forth in Section 3.6(d). 

1.68. “SUSAR” means a suspected unexpected serious adverse reaction resulting from any Clinical Trial or administration of a
Product. 
 1.69. “Target” means, [***]. If a Target is [***], and if a Target is [***]. A Target shall [***]. By way of
example, if a Target is [***], it includes: (a) [***] such Target [***], and (b) [***] of such Target or variant thereof. “Target”, “Targeting” or “Targeted” means, when used as a verb, [***]. 

  
 - 10 - 

 Confidential 
  

 1.70. “Target Candidate” means any candidate Target which Legend nominates
and makes notice in writing to Target Reviewer for review. 
 1.71. “Target Reviewer” means an independent reviewer [***].

 1.72. “Taxes” has the meaning as set forth in Section 10.7. 

1.73. “TCR-T” means engineered T-cells that
express a T-cell receptor on their cell membrane, which [***]. 
 1.74. “Territory”
means worldwide. 
 1.75. “Third Party” means a person or entity other than the Parties and their respective Affiliates.

 1.76. “Third Party Claims” has the meaning as set forth in Section 16.1. 

1.77. “Treaty” has the meaning as set forth in Section 10.7. 

1.78. “Valid Claim” means an issued and unexpired claim of a Licensed Patent, including any additional term provided by a SPC
(supplementary protection certificate or its equivalent), existing in a country or area in the Territory that claims the composition of matter of the applicable Licensed Compound or Licensed Product in that country and that 1) has not been revoked
or held invalid or unenforceable by a decision of a court or other governmental agency of competent jurisdiction, and 2) has not been denied or admitted to be invalid or unenforceable through reissue,
re-examination, disclaimer or otherwise by Noile. 
 1.79. “Work Results” means any
Intellectual Property and any source information and data relevant to such Intellectual Property invented, developed or otherwise made by or on behalf of a Party (or Parties) in the course of all activities under this Agreement including but not
limited to the Initial Research, Development and Commercialization activities (whether or not patentable or subject to copyright or trade secret protection). For clarity, Work Results shall include raw data, laboratory notebooks and materials, if
any. 
 2. GOVERNANCE 
 Legend
and Noile agrees to cooperate with each other in good faith [***] in accordance with the terms and conditions of this Agreement. Without limiting the generality of the foregoing and any other obligations of Legend under this Agreement, Legend will
notify Noile, [***] any milestone achievement [***]. In addition, Noile is entitled to request Legend to disclose [***] which Legend will not unreasonably reject or withhold, [***]. 

  
 - 11 - 

 Confidential 
  

 3. TARGET NOMINATION, SELECTION AND SUBSTITUTE 

3.1. Legend’s Right. 

(a) Subject to Section 3.6, during the Initial Research Term, Legend has the right to nominate up to two (2) Legend Selected Targets
for evaluating, researching or developing Licensed Compounds and/or Licensed Products. For clarity, and notwithstanding anything to the contrary in this Agreement, Legend is [***] 

(b) During the valid term of the Substitute Option Right, Legend shall have the right to convert each Legend Selected Target into a Licensed
Target by providing written notice to Noile, which Licensed Target fully enjoys the Commercial License with sublicensing right under Section 7.4, provided however, it will automatically lose the Substitute Option Right with respect to the
converted Legend Selected Target after such conversion. 
 (c) Furthermore, Legend shall have the right within the valid term to exercise
the Substitute Option Right by substitution from any Legend Selected Target based upon the provisions set forth in Section 3.6(a). 

3.2. Nomination. Following the Effective Date, Legend may nominate Target Candidates by providing written notice to the Target Reviewer
of such Target Candidates, that Legend proposes to become Licensed Targets finally. This right of nomination is exercisable by Legend throughout the Initial Research Term until all Legend Selected Targets have been finally determined in accordance
with this Agreement, subject to Section 3.6; provided, however, that such right of nomination shall be exercised at any one time only in relation to a maximum number of Target Candidates which is equal to the number of Legend Selected Targets
which remain unselected at the time of the exercise. Upon receiving a written notice from Legend which is compliant with this Section 3.2, the Target Reviewer shall promptly (and in no event later than [***] days after such receipt) make
written notice, with a copy to Legend, to Noile of the fact of the nomination, the date on which the Target Reviewer received the written notice from Legend (the “Priority Date”), and the number of Target Candidates nominated by
Legend in its written notice to the Target Reviewer, without disclosing to Noile [***] such Target Candidates. 
 3.3. Selection.
Upon notice to Noile by the Target Reviewer under Section 3.2, Noile shall [***] provide the Target Reviewer with a list of all Targets, (a) to which Noile has licensed exclusive rights to a Third Party, or is otherwise contractually
restricted from licensing any right to Legend, evidenced by the relevant exclusive license agreements or other contracts; (b) which Noile has entered into (and has maintained ongoing) active discussions with a Third Party with respect to a
potential agreement, which when executed, would be described in sub-Section (a) above, with such discussions being evidenced by [***] (“Ongoing Bona Fide Discussions”); and (c) to
which Noile has itself already initiated and maintained [***] specific to a Product Targeting such Target, as evidenced by [***] (“Noile Research”); in each case 

  
 - 12 - 

 Confidential 
  

 of sub-Sections (a) through (c) above, as of the Priority Date
(the “List”, and the Targets on the List, the “Excluded Targets”). The Target Reviewer shall verify the list and the evidence provided by Noile, select the Target(s) among the Target Candidates which do not fall
under the Excluded Targets, and notify Legend, in writing with a copy to Noile, of the result of the selection operation. 
 3.4.
Designation of Each Legend Selected Target. Immediately upon the notification from the Target Reviewer under Section 3.3 that a Target Candidate nominated by Legend is not an Excluded Target, such Target shall be deemed a “Legend
Selected Target”. For clarification, this event shall be the direct trigger for the Initial Payment for the applicable Legend Selected Target under Section 9.1. For clarity, and subject to Section 3.6, Legend has the right to
nominate any Legend Selected Target only within the Initial Research Term, that is [***] after the Effective Date; provided, however, that the period during which Legend has the right to nominate any Legend Selected Target shall be tolled for [***]
and the Initial Research Term shall be extended by such duration. 
 3.5. Updated Arrangements. Unless and until two (2) Legend
Selected Targets have been finally selected in accordance with this Agreement, Legend may continue exercising the right of nomination provided for in Section 3.2, within the Initial Research Term only (but subject to Section 3.6), by
providing written notice to the Target Reviewer of new Target Candidates and/or past Excluded Targets in accordance with Section 3.2. The Target Reviewer shall follow the procedure set forth in Section 3.2 in notifying Noile of any and all
new nominations made by Legend, and Noile shall follow the procedure set forth in Section 3.3 in providing the Target Reviewer updates to the List upon receiving the notice from the Target Reviewer of new nominations made by Legend. Such
updates may include, but are not limited to, addition of new Excluded Targets (with corresponding evidence as required in Section 3.3) and removal of past Excluded Targets from the List (due to, for example, termination of exclusive license
agreements or other contracts with Third Parties, termination of Ongoing Bona Fide Discussions, or termination of Noile Research). The Target Reviewer shall then follow the procedure set forth in Section 3.3 in notifying Legend any and all new
Target(s) selected by it. Up to two (2) Legend Selected Targets can be initially designated by both Parties during the Initial Research Term. If the number of the Legend Selected Targets initially designated during the Initial Research Term is
less than two (2), no extension of the Initial Research Term is permitted for further selection of initial Legend Selected Targets. However, if no Legend Selected Target is selected during the Initial Research Term, both Parties shall consult in
good faith to find a solution, including, without limitation, termination of this Agreement. 
 3.6. Substitute of Target. 

(a) Notwithstanding anything herein to the contrary, Legend shall have, after the initial designation of a Legend Selected Target, an
option to substitute such Legend Selected Target with a new Target, which option may be exercised by Legend [***], with respect to each initially designated Legend Selected Target (referred to as “Substitute Option Right”). Any such
Substitute Option Right shall be valid and exercisable, on a Legend Selected Target-by-Legend Selected Target basis, [***]. 

  
 - 13 - 

 Confidential 
  

 (b) Each substitution under Section 3.6(a) shall be [***] relating to such Target (or a
Licensed Compound or a Licensed Product relating to such Target), based upon which [***]. In the case where Legend desires to replace a Target with any proposed Target Candidate, Legend, the Target Reviewer and Noile shall follow the procedures set
forth in Sections 3.2-3.4 in selecting the replacement Legend Selected Target. Additionally, Legend shall [***] to replace the Target. 

(c) For clarity, Legend shall have [***]. If Legend desires [***] to this Agreement under the terms and conditions to be mutually agreed upon.

 (d) Any Legend Selected Target as replaced with a new Target shall no longer become a Licensed Target (herein referred to as
“Substituted Target”) nor be covered by the Research License under Section 7.1. 
 4. RESEARCH AND DEVELOPMENT PLAN 

4.1. Research and Development Plan. Following the designation of each Legend Selected Target in accordance with Section 3, Legend
shall, upon good faith discussion with Noile, use Commercially Reasonable Efforts to determine a Research and Development Plan covering [***] research and development activities for Licensed Compounds and Licensed Products Targeting such Legend
Selected Target, and as required to enable the filing of an approval by Legend for a Licensed Product Targeting the Licensed Target [***]. Legend shall consider in good faith any suggestions or comments from Noile (if any) in relation to the
preparation of a Research and Development Plan, but shall have the final decision on all matters of such Research and Development Plan to the extent it is compliant with the terms and conditions of this Agreement; provided, however, that if such
Research and Development Plan obligates Noile to perform specific scientific and/or technical activities which are assigned to Noile, Noile’s prior consent (which shall not be unreasonably withheld) shall be required with respect to such
assignment of activities to Noile. 
 4.2. Performance of Research and Development Plan 

(a) Under each Research and Development Plan, Legend shall use Commercially Reasonable Efforts to perform the Research and Development Plan.
Legend will provide Noile with [***] reports in reasonable form and substance in relation to updates to the progress of the relevant Research and Development Plan. 

(b) Upon request by Legend and agreement by Noile (which shall not be unreasonably withheld), Noile shall provide reasonable technical support
to facilitate and speed up the research as stated in the relevant Research and Development Plan; provided, however, that [***]. Further, both parties shall discuss in good faith considering each other’s suggestion in relation to the Research
and Development Plan at each stage. 

  
 - 14 - 

 Confidential 
  

 4.3. Subcontractors. Each Party may subcontract portions of its work as necessary
under the Research and Development Plan to (i) any Affiliate or (ii) Third Parties; provided in the case of a Third Party, (a) [***], and (b) such subcontract is in writing and is consistent with the terms and conditions of this
Agreement including the confidentiality provisions of Section 12 and any rights granted to such subcontractor are restricted to only those rights necessary for performance by such subcontractor of the portions of work on behalf of the sub-contracting Party. The sub-contracting Party shall remain fully responsible (at its cost) for all acts or omissions of any subcontractor it appoints (including any acts or
omissions which result in a breach of the terms of this Agreement) and shall ensure that each subcontractor complies with the terms and conditions of this Agreement. 

4.4. Completion of any Research and Development Plan. The term for a particular Research and Development Plan shall commence on the
start date for such Research and Development Plan, and shall continue, unless earlier terminated in accordance with Section 17, until [***] in the Research and Development Plan. For the avoidance of doubt, and notwithstanding anything herein to
the contrary, under no circumstances shall Legend be obligated to disclose or provide to Noile any of Legend’s technology, data, information, know-how, trade secrets, materials (including biological
materials), compounds, procedures or inventions, in each case invented, developed, created or otherwise made by, for or on behalf of Legend or its Affiliates prior to the Effective Date or after the Effective Date but independently of this
Agreement. 
 4.5. Reports and Records. 

(a) Progress Reports. Legend shall keep Noile [***] informed of its progress under each relevant Research and Development Plan,
including with respect to any milestone achievement. All such reports, information and data provided by a Party shall be considered the providing Party’s Confidential Information and, as between the Parties, shall be exclusively owned by the
providing Party. 
 (b) Development Records. Legend shall maintain records of its performance of each Research and Development Plan
(or cause such records to be maintained) in sufficient detail and in good scientific manner as shall properly reflect all work done and results achieved in the performance of such Research and Development Plan. All laboratory notebooks shall be
maintained for [***] of the relevant notebook entry. All other records shall be maintained by each Party during the applicable Research and Development Plan [***]. All such records of a Party shall be considered such Party’s Confidential
Information and, as between the Parties, shall be exclusively owned by such Party. 
 (c) Quality. Each Research and Development Plan
shall be performed at all times in accordance with all Applicable Laws including as applicable requirements of GxP. 

  
 - 15 - 

 Confidential 
  

 4.6. Research Efforts. Each Party may assign such scientific and technical personnel
and allocate such other resources as such Party judges are reasonably necessary for performing the activities as are assigned to it in each Research and Development Plan and shall perform such activities in accordance with all Applicable Laws
(including GxPs) in each case to the extent applicable to performance of the relevant Research and Development Plan activities by such Party and the terms and conditions of this Agreement. Each Party shall be solely responsible for the safety and
health of its employees, consultants and visitors, and for compliance with all Applicable Laws related to health, safety and the environment, including providing its employees, consultants and visitors with all required information and training
concerning any potential hazards involved in performing such activities and any precautionary measures to protect its employees from any such hazards at its own facilities and as regards its or its subcontractors’ performance of the Research
and Development Plan. Each Party shall use Commercially Reasonable Efforts to [***] in each Research and Development Plan. 
 4.7.
Conduct of Clinical Trials. Legend agrees that any Clinical Trial with respect to a Licensed Product will be conducted under an IND and in accordance with applicable GxPs. 

5. DEVELOPMENTS AND REGULATORY APPROVAL 

5.1. As between the Parties, Legend shall be responsible for holding and applying for any Regulatory Approvals or MAAs in relation to the
Licensed Products and the Licensed Compounds, and for sponsoring any Clinical Trials (including holding the IND). Legend shall have sole decision-making authority in relation to any sponsorship of any Clinical Trials or progression of any Licensed
Products through Clinical Trials, including the decision on whether to apply for any MAAs. 
 5.2. Legend shall use Commercially Reasonable
Efforts to develop the Licensed Products and obtain Regulatory Approval at its own responsibility and expense in the Territory. 
 5.3.
Legend shall more specifically use Commercially Reasonable Efforts to satisfy the following obligations: 
 (a) Submit the first (1st) IND for a Licensed Compound (or Licensed Product) to a Regulatory Authority in a Major Country within [***]; and 

(b) Have the First Commercial Sale of a Licensed Compound (or Licensed Product) in a Major Country within [***]. 

For the avoidance of doubt, the above obligations are indicative of Commercially Reasonable Efforts [***], and Legend shall still continue to
use a reasonably similar level of effort after Legend completes the above obligations. 
 5.4. In the event that Noile in good faith
believes that Legend is not meeting its diligence obligations, and Legend has not achieved one of the above diligence milestones by the corresponding target date, then within [***] of Noile’s written request for the Parties to meet, the Parties
shall [***] for the Parties to discuss Legend’s progress toward the [***]. If, following the [***] meeting, [***] that Legend is satisfying its diligence obligations despite the fact that Legend has not achieved a development milestone by the
corresponding target date, then the Parties shall, in good faith, discuss and mutually agree upon a new target date for the achievement of such development milestone, based upon the then-expected development environment. 

5.5. If, following the above [***] meeting, Legend [***] this Agreement, and, should that [***], then Legend shall, [***], either (i) [***],
or (ii) [***]. In the event of the above (i), the Parties [***]. 

  
 - 16 - 

 Confidential 
  

 5.6. Legend shall provide Noile with [***] written progress reports summarizing the events,
schedule, and progress of the Development, registration, and estimated launch dates for each Licensed Product, [***]. Such reports shall be considered Legend’s Confidential Information and, as between the Parties, shall be exclusively owned by
Legend. 
 5.7. For the avoidance of doubt, all Licensed Compounds and Licensed Products as necessary for the development hereunder shall be
made or had made by Legend at its own responsibility and expense. 
 6. COMMERCIALIZATION 

6.1. Commercialization Generally. Legend shall use its Commercially Reasonable Efforts to Commercialize any Licensed Product following
its decision to progress filing an IND in relation to such Licensed Product. Legend shall be primarily responsible for and shall have sole decision making authority in relation to the Commercialization and manufacture of the Licensed Product
following filing of IND. 
 6.2. Commercialization Updates. Legend shall keep Noile informed of its Commercialization of any Licensed
Product and shall provide [***] updates to Noile summarizing progress in the Development and Commercialization of any Licensed Products in relation to which any Research and Development Plan has been completed. All such updates shall be considered
Legend’s Confidential Information and, as between the Parties, shall be exclusively owned by Legend. 

  
 - 17 - 

 Confidential 
  

 6.3. Safety Event Reporting. Additionally, each Party shall provide to the other Party
prompt written notice of any material safety events pertaining to any Product, including a Product developed by any third party, of which it becomes aware including any SUSARs, SAEs or other material events which [***]; provided, however, that
nothing under this Section 6.3 shall require any Party to breach its obligations to any Regulatory Authority under Applicable Law and/or its confidentiality obligations to any third party under
non-disclosure agreements or other similar agreements. 
 7. GRANT OF LICENSE 

7.1. Research License. Noile agrees to grant and hereby grants to Legend, and Legend agrees to accept and hereby accepts from Noile, an
exclusive license, without the right to grant sublicense, under the Licensed Patent and the Licensed Know-How, to research and develop Licensed Compounds and Licensed Products targeting any of the Legend
Selected Targets or the Licensed Targets in the Field in the Territory (the “Research License”). 
 7.2. Expiration of
Research License. The Research License shall terminate upon [***]. 
 7.3. Commercial License. With respect to each
Legend Selected Target and each Licensed Target, Noile agrees to grant and hereby grants to Legend, and Legend agrees to accept and hereby accepts from Noile, an exclusive license (with the right to grant sublicenses through multiple tiers of
sublicensees) under the Licensed Patent and the Licensed Know-How, to research, Develop, make, have made, use, sell, offer for sale, export and import Licensed Compounds and Licensed Products Targeting such
Legend Selected Target or the Licensed Target (as applicable) in the Field in the Territory (the “Commercial License”). For the avoidance of doubt, the Commercial License shall immediately be invalidated with respect to any Legend
Selected Target upon its becoming a Substituted Target. 
 7.4. Sublicense. Legend shall be fully responsible for the acts or
omissions of its Affiliates under this Agreement, the acts or omissions of the Sublicensees under this Agreement, and the sublicensing of the Licensed Patents and the Licensed Know-How in the Field. Legend
shall be obliged to [***]. 
 7.5. Target Exclusivity. During the term of this Agreement, neither Noile nor any of its Affiliates
shall work independently of this Agreement on any Legend Selected Target (so long as such Legend Selected Target does not become a Substituted Target) or any Licensed Target, for itself or through or with its respective Affiliates or any Third Party
(including the grant of any license or option to its Affiliates or any Third Party), to discover or otherwise research and/or Develop and/or Commercialize any Product that binds any Legend Selected Target (so long as such Legend Selected Target does
not become a Substituted Target) or any Licensed Target. 

  
 - 18 - 

 Confidential 
  

 8. TECHNOLOGY TRANSFER  

8.1. Technology Transfer. Within [***] days after the date of the designation of each Legend Selected Target, and thereafter during the
term of this Agreement pursuant to Section 1.53 in relation to applicable advances and/or improvements after the Effective Date, Noile shall provide access to Legend all available data and know-how
applicable to Noile Platform and such Legend Selected Target or Licensed Target, as applicable, that are available to Noile as of the date of the designation of such Legend Selected Target and which are necessary or useful for the research,
Development and Commercialization of Licensed Compounds and Licensed Products for such Legend Selected Target or Licensed Target, as applicable; provided, however, that nothing under this Section 8.1 shall require Noile to breach its
obligations to any Regulatory Authority under Applicable Law and/or its confidentiality obligations to any third party under non-disclosure agreements or other similar agreements. Such data, know-how and technology shall include but not limited to [***]. 
 8.2. Material Transfer. During
the Initial Research Term, Noile may, at its discretion, provide Legend with materials (collectively, “Noile Materials”), as is agreed to by the Parties in accordance with the Research and Development Plan. In such event, Noile
shall disclose at least reasonably sufficient information to handle or maintain such Noile Materials safely. Other details of the transfer of each of Noile Materials, including quality and quantity thereof, the detailed timing and mode of transfer,
shall be separately determined between the Parties; [***]. In furtherance of the foregoing, unless otherwise agreed to by the Parties in a separate agreement, it is agreed upon that: 

(a) Legend may use Noile Materials for the purpose of the Initial Research or for any other
non-commercial or commercial purpose in connection with Licensed Compounds and/or Licensed Products; 

(b) Legend shall not transfer Noile Materials in part or whole to any Legend Personnel or Third Party to perform any activities inconsistent
with the Research License or the Commercial License (including any sublicense thereof), without the prior written consent of Noile; 
 (c)
Legend’s rights under Sections 8.2(a) and 8.2(b) shall not terminate until expiration or termination of the Research License and Commercial License with respect to each Legend Selected Target and Licensed Target; and 

(d) unless otherwise specifically provided herein, Noile shall retain all right, title and interest in and to any and all Noile Materials, and
Legend shall, upon expiration or termination of the Research License and Commercial License with respect to each Legend Selected Target and Licensed Target: (i) either destroy Noile Materials and provide Noile with written evidence of such
destruction or return to Noile, all of the unused Noile Materials; and (ii) cease all work employing such Noile Materials; and 

  
 - 19 - 

 Confidential 
  

 (e) Legend acknowledges that Noile Materials are experimental in nature and they are provided
WITHOUT WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR ANY OTHER WARRANTY, EXPRESS OR IMPLIED. NOILE MAKES NO REPRESENTATION OR WARRANTY THAT THE USE OF NOILE MATERIALS SHALL NOT INFRINGE ANY PATENT OR OTHER PROPRIETARY RIGHTS.

 9. CONSIDERATION 
 9.1.
Initial Payments for each Legend Selected Target. Within [***] days after the designation of each Legend Selected Target (under Section 3.4) on a Legend Selected Target-by-Legend Selected Target
basis, Legend shall pay to Noile an Initial Payment for each Legend Selected Target in the amount of [***] via wire transfer of immediately available funds to the bank account as specified in Exhibit B. The total payments under this Section
shall [***] and no payments shall be due on designation of any other Target than Legend Selected Target. For clarity, [***]. 
 9.2.
Notification and Milestone Payments. Legend shall [***] notify Noile in writing of the achievement of each milestone event described in the table below and, within [***] of the event, shall remit the applicable Milestone Payment to Noile via
wire transfer of immediately available funds to the bank account as specified in Exhibit B with respect to any first Licensed Compound or Licensed Product (whichever is earlier) reaching each of the events below for each Licensed Target: 

 

			
	 Development Events
	  	Milestone Payments
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	    

 Milestone payments listed above shall be made only once upon the first achievement of each relevant milestone
by the first Licensed Compound or Licensed Product (whichever is earlier) for each Licensed Target, and shall be payable no more than two (2) times each (once per each Licensed Target). For the avoidance of doubt, a Milestone Payment shall be
due and payable regardless of whether it is Legend or any Affiliate achieving such milestone event or any Third Party achieving such milestone event on behalf of Legend or its Affiliates. 

  
 - 20 - 

 Confidential 
  

 9.3. Royalties. In partial consideration for the rights and licenses granted herein,
Legend shall pay to Noile, during the Royalty Term and on a country-by-country and Licensed
Product-by-Licensed Product basis, a running royalty as specified below on the Net Sales of the Licensed Products sold by Legend, its Affiliates and/or Sublicensees,
which royalty shall not be refundable nor creditable. 
  

			
	 (A) Annual, worldwide Net Sales of all Licensed Products, except for the case (B) in the row
below.
	 	[***] of Net Sales
		
	 (B) Annual, worldwide Net Sales of all Licensed Products in the applicable Generic/Biosimilar
Competition Period.
	 	[***] of Net Sales

 If, during the applicable Royalty Term, a Licensed Product is not covered by a Valid Claim in a Licensed
Patent in a country, the royalties owed by Legend on the Net Sales of such Licensed Product in such country sold by Legend, its Affiliates and/or Sublicensees shall be reduced by [***]. 

In accordance with Section 10.1., Legend shall report to Noile on Net Sales on a Licensed Product-by-Licensed Product and country-by-country basis as long as any obligation to pay royalties for Licensed Products
exists. 
 9.4. Third Party Royalties. If Legend is required to pay patent royalties to a Third Party for an unblocking license
permitting the manufacture or sale of Licensed Products, then [***]. [***] paid by Legend under such third-party license shall be creditable against the royalties due Noile; provided that the royalties payable to Noile in a given calendar year shall
[***]. For clarification, [***]. It is understood that no such royalty deduction may be granted for Third Party royalties due on account of [***]. For clarity, Legend would be responsible for the payment of any and all royalties and all other
payments owed to Third Parties with respect to Licensed Targets under any agreements between Legend and such Third Parties as of or following the Effective Date. 

10. PAYMENTS BY LEGEND 
 10.1.
Royalty Payments and Report of Sales Amounts. Within [***] days from the end of each Calendar Quarter, Legend shall make payment of the royalties due for such Calendar Quarter. Together with the payment, Legend shall also send Noile a report
for such Calendar Quarter setting forth the Net Sales of the Licensed Products in such Calendar Quarter along with its calculation of the royalty due. Legend shall keep accurate records in sufficient detail to enable any payment payable hereunder to
be determined. 

  
 - 21 - 

 Confidential 
  

 10.2. Payment Account. The applicable parts of Sections 10.1 through 10.7 shall apply
to the Initial Payments under Sections 9.1, the Milestone Payments under Section 9.2, and the royalty payments under Section 9.3. All payments to Noile including the Initial Payments, the Milestone Payments, and royalty payments shall be
made by wire transfer to an account of Noile set forth in Exhibit B attached hereto. 
 10.3. Currency. All amounts payable by
Legend under this Agreement shall be paid in United States Dollars. In the case of sales outside the United States, the rate of exchange to be used in computing the amount of royalty payments due Noile shall be made [***]. If, due to restrictions or
prohibitions imposed by national or international authority, payments cannot be made as provided in this Section 10, the Parties shall consult with a view to finding a prompt and acceptable solution. 

10.4. Right to Audit. Noile shall have the right, upon prior written notice to Legend, not more than [***], through an independent
certified public accountant selected by Noile and reasonably acceptable to Legend, which acceptance shall not be unreasonably withheld or delayed, to inspect or audit the relevant records of Legend to verify that the amounts of royalty payments were
correctly determined. The independent certified public accountant shall execute a confidentiality agreement, in a form reasonably acceptable to Legend, with respect to all information provided by Legend. Legend shall grant the independent certified
public accountant access during normal business hours to those books and records of Legend concerning Licensed Products as may be reasonably necessary for the sole purposes of verifying the accuracy of the reports required to be furnished by
Legend, pursuant to Section 9.3 and Section 10.1; provided, however, that verification shall [***]. The records and results of such audits shall be deemed Confidential Information of Legend and, as between the Parties, shall be exclusively
owned by Legend. A copy of the independent certified public accountant’s report shall be delivered to Legend simultaneously with its delivery to Noile. If the independent certified public accountant’s report correctly shows any
underpayment of royalties by Legend, Legend shall remit to Noile within [***] days after Legend’s receipt of such report: 
  

	 	a)	 the amount of such underpayment; 

 

	 	b)	 interest on the underpayment which shall be calculated pursuant to Section 10.5; and

  

	 	c)	 the reasonable fees and expenses of the independent certified public accountant performing the audit, if such
underpayment exceeds [***]. Otherwise, Noile’s accountant’s fees and expenses shall be borne by Noile. 

 10.5.
Overdue Payment. In the case of a delay in payment not caused by Force Majeure, interest on any overdue payments shall accrue at a rate of [***], effective for the applicable days of the period of default. 

10.6. Record of Sales: Notwithstanding anything herein to the contrary, Legend shall keep, or cause to be kept, records of the sales of
the Licensed Products under this Agreement for a period of [***]. Upon request by Noile, Legend shall supply Noile with such records, which may be submitted to the tax authority, and shall give Noile any commercially reasonable assistance in
relation thereto. Such records shall be deemed Confidential Information of Legend and, as between the Parties, shall be exclusively owned by Legend. 

  
 - 22 - 

 Confidential 
  

 10.7. Taxes: Noile shall be liable for all income and other taxes (including interest)
(“Taxes”) imposed upon any payments made by Legend to Noile under this Agreement. No Taxes shall be deducted from the payments made under this Agreement, except that Legend may withhold from any amounts payable hereunder any Taxes
which are required to be withheld by Applicable Laws. Noile shall cooperate with Legend and make commercially reasonable efforts in order to (i) file certificates and other documentation with tax authorities and (ii) obtain a reduction or
elimination of, or credit for, Taxes relating to this Agreement. Without limitation of the generality of the foregoing, in order to eliminate the obligation to withhold Taxes under the United States-Japan Income Tax Treaty effective as of
March 30, 2004 (hereinafter referred to as the “Treaty”), Noile may complete the Application Form (ex.W-8BEN) for Income Tax Convention and the Attachment Form For Limitation On Benefits
Section and send them to Legend. Legend agrees that, once Noile has taken all steps necessary for applying the Treaty in a timely manner as provided in this Section, Legend shall not withhold such Taxes unless required by Applicable Law. If,
however, Legend determines that it is required by Applicable Law to withhold any Taxes, and such Taxes are withheld and paid by Legend to the appropriate tax authority, then Legend shall provide Noile with an official tax receipt or other evidence
issued by the tax authority to support a claim for credit by Noile within [***] days of Legend’s receipt of the official tax receipt or evidence from the tax authority. 

11. INTELLECTUAL PROPERTY AND PATENT INFRINGEMENT 

11.1. Ownership. 
 (a)
Ownership of all Work Results, including any Intellectual Property developed in the course of the preclinical development or clinical development of any Licensed Product, shall be determined by inventorship or authorship, as applicable. Inventorship
and authorship determination shall be in accordance with [***]. Notwithstanding the above, if the Work Results to the extent [***] then Legend shall solely own the Work Results including but not limited to the relevant intellectual property, know-how, trade-secret etc. and administer that on its sole discretion for any purpose and Noile hereby assigns to Legend all of its rights, title and interest in and to such Work Results, and all intellectual
property, know-how, trade secret and other proprietary rights therein. [***] 
 (b) For the
avoidance of doubt, any background Intellectual Property developed before the Effective Date shall remain separately owned by the Party who independently developed such Intellectual Property, and nothing under this Agreement shall affect or impact
any ownership of either Party in relation to such Party’s background Intellectual Property. 
 11.2. Intentionally Omitted. 

11.3. Prosecution. Legend shall have the first option to institute, prosecute, and control, at its own expense and by counsel of its
own choice, any action or proceeding with respect to infringement of any Licensed Patents relating to the manufacture, use, importation, sale, or offer for sale of any Licensed Product being Developed or Commercialized in the Territory. Legend shall
have the sole right to institute, prosecute, and control, at its own expense 

  
 - 23 - 

 Confidential 
  

 
and by counsel of its own choice, any action or proceeding with respect to infringement of any of Legend’s patents relating to Licensed Products. Any amount recovered by Legend as a result
of such an action, by settlement or otherwise, shall be [***]. If Legend fails to bring an action or proceeding or otherwise fails to take appropriate action to abate such infringement within a period of [***] starting from the giving of notice by
Noile to Legend of any infringement or threatened infringement by a Third Party of any Licensed Patent, Noile shall have the right, but not the obligation, to bring and control, at its own expense and by counsel of its own choice, any action or
proceeding relating to the Licensed Patent. Any recovery obtained by Noile as a result of such an action, by settlement or otherwise, shall be [***]. The Party not taking action to respond to any such action shall provide reasonable assistance to
the Party taking such action, including, to the extent necessary to allow the Party taking such action to maintain the action, providing access to relevant documents and other evidence, and making its employees available at reasonable business
hours. Noile shall not be required to join an action as a party if Legend desires to bring an action in court unless such action is taken by Legend, based on reasonable considerations, in a jurisdiction that requires Noile to be a plaintiff. 

11.4. Settlement. In no case may Legend enter into any settlement or consent judgment or other voluntary final disposition that:
(i) extends, or purports to exercise, Legend’s rights under the Licensed Patents beyond the rights granted pursuant to this Agreement, (ii) makes any admission regarding wrongdoing by Noile, or the invalidity, unenforceability or
absence of infringement of any Licensed Patent; (iii) [***] (iv) subjects Noile to an injunction or other equitable relief; or (v) obligates Noile to make a monetary payment; in all cases without the prior written consent of Noile, which
consent shall not be unreasonably withheld or delayed. Similarly, in no case may Noile enter into any settlement or consent judgment or other voluntary final disposition that: (a) limits Legend’s rights under the Licensed Patents or under
this Agreement other than as expressly stated herein; (b) makes any admission regarding wrongdoing on the part of Legend, an Affiliate or Sublicensee, or the invalidity, unenforceability or absence of infringement of any Intellectual Property
right arising hereunder or any Licensed Patent; (c) subjects Legend, an Affiliate or Sublicensee to an injunction or other equitable relief; or (d) obligates Legend, an Affiliate or Sublicensee to make a monetary payment; in all cases
without the prior written consent of Legend, which consent shall not be unreasonably withheld or delayed. 

  
 - 24 - 

 Confidential 
  

 11.5. [***] shall, at its own cost, maintain responsibility for the preparation,
filing, prosecution, and maintenance of any and all patents and patent applications included in the Licensed Patents. [***] agrees to retain a patent law firm and/or patent agent to handle all preparation, filing, prosecution, and maintenance of the
patents and patent applications within the Licensed Patents. [***] shall be the client of the patent law firm and/or patent agents. In particular, [***] shall keep [***] informed of any official communication from [***], but only to the extent when
such communication relates to matters which would be reasonably expected to adversely affect such Licensed Patents (including any official actions limiting the scope of a claim, citations of prior art, rejections, interferences, oppositions,
reexaminations, revocations or nullifications). For the avoidance of doubt, nothing under this Section 11.5 obligates [***] to consult, or otherwise requires [***] in relation to any preparation, filing, prosecution, and maintenance of patents
and patent applications included in the Licensed Patents, which shall be performed under [***]. 
 11.6. If reasonably requested by [***]
shall cooperate fully in the preparation, filing, prosecution and maintenance of the Licensed Patents and in the obtaining and maintenance of any patent extensions, supplementary protection certificates and the like with respect to any Licensed
Patents, including executing all papers and instruments, or requiring their respective employees or contractors to execute such papers and instruments, so as to effectuate the ownership of the Licensed Patents. 

12. CONFIDENTIAL INFORMATION 

12.1. Confidentiality. Except as otherwise expressly provided in this Agreement or otherwise agreed to in writing, each Party shall
hold, and shall cause its or its Affiliates’ directors, officers, faculty, employees, contractors, subcontractors, consultants, advisors and agents to hold, in confidence all Confidential Information of the other Party furnished to it or its
Affiliates by or on behalf of the other Party or the other Party’s Affiliates, or acquired by it or its Affiliates, or its or its Affiliates’ directors, officers, faculty, employees, contractors, subcontractors, consultants, advisors and
agents as required or permitted under this Agreement and shall only disclose such Confidential Information to its or its Affiliates’ directors, officers, faculty, employees, contractors, consultants, advisors and agents having a need to know
such Confidential Information. Except as otherwise expressly provided in this Agreement or otherwise agreed to in writing, neither Party shall use any such Confidential Information except for the purposes contemplated by this Agreement and as set
forth in Section 12.2 or release or disclose such Confidential Information to any other person, except its Affiliates or its or its Affiliates’ directors, officers, faculty, employees, contractors, consultants, advisors and agents as
needed for such Party’s performance of the transactions contemplated by this Agreement, and its auditors, attorneys, financial advisors and bankers in the ordinary course of its business, each of whom has agreed in writing to be bound by
obligations of confidentiality no less restrictive than those that bind the Parties under this Agreement. The obligations of this Section 12 shall continue with respect to all Confidential Information until [***]. 

  
 - 25 - 

 Confidential 
  

 12.2. Legal Exclusion. Notwithstanding Section 12.1, either Party may disclose
the Confidential Information of the other Party to the extent such disclosure is required by a court or applicable administrative order, law or regulation; provided that, to the extent permitted by Applicable Law, such Party promptly provides
written notice to the other Party and cooperates with the other Party to minimize the scope of disclosure, and seeks a protective order to prevent disclosure of such information. If, in the absence of a protective order or other remedy, such Party
is[***] compelled to disclose any such Confidential Information to any tribunal or other entity, such Party may disclose such Confidential Information without liability hereunder; provided that such Party gives prior written notice (to
the extent permitted by Applicable Law) to the other Party and copies of the Confidential Information to be disclosed. Any information disclosed under this Section 12.2 shall remain confidential for all other purposes; provided that such
information continues to be Confidential Information. 
 12.3. Responsibility. Without limiting the generality of any other clause
herein including without limitation Section 7.4, each Party shall be responsible for any breach of this Section 12 by its Affiliates or its or its Affiliates’ directors, officers, employees, contractors, subcontractors, consultants,
advisors or agents. 
 12.4. [***] Covenant. 

(a) Each Party hereby covenants not to [***] the other Party regarding the [***] which such Party may [***] hereunder, for the other
Party’s [***] through contract research organizations or “bona fide Third Party collaborators”; provided that neither Party shall [***] such contract research organizations or Third Party collaborators who have [***] the Parties under
this Agreement. 
 (b) The covenant in Section 12.4(a) shall not: (i) be construed to give either Party [***] the other Party,
with any [***]; or (ii) restrict any rights that either Party may have under applicable [***] law, for example, but without limitation, [***]. 

(c) The term “bona fide Third Party collaborators” used in Section 12.4(a) means: (i) [***] Third Party who enters into a
written agreement with a Party to conduct collaborative research [***]; or (ii) [***] Third Party who enters into a written agreement with a Party to conduct collaborative research. 

  
 - 26 - 

 Confidential 
  

 13. PUBLICATION 

13.1. In case a Party desires to publish or otherwise disclose in public any Work Results, such Party shall furnish the other Party with a copy
of any proposed written or oral publication or presentation (including manuscripts, abstracts, and oral presentations) at least [***] days prior to submission for publication or presentation. The other Party shall promptly notify in writing the
Party desiring to publish or present if any action is necessary to delete or redact any Confidential Information of the other Party or to file for patent protection of any Work Results proposed to be disclosed in the written or oral publication or
presentation. The Party desiring the publication shall: (i) delete or redact any Confidential Information identified in a notice(s) by such other Party, and/or (ii) delay publishing such proposed publication for a maximum of [***] days in
order to allow for patent protection of the Work Results to be secured. 
 13.2. Each Party recognizes the need to secure patent
applications to protect the value of inventions made in the Initial Research. Therefore, in case of Section 13.1(ii), the Parties shall work in good faith to properly secure patent applications in a timely manner and establish a publication
process that preserves the ability of the Parties to maximize patent protection while publishing results in a reasonable timeframe. Each Party shall have the right to participate in publications as authors when appropriate. 

14. REPRESENTATIONS AND WARRANTIES 

14.1. Mutual Representations and Warranties. Each Party warrants and represents to the other Party as of the Effective Date that: 

(i) it is a corporation duly organized, validly existing, and in good standing under the laws of its jurisdiction of formation, and it has full
corporate power and authority to execute, deliver, and perform this Agreement and has taken all corporate action required by Applicable Law and its organizational documents to authorize the execution and delivery of this Agreement and the
consummation of the transactions contemplated by this Agreement; 
 (ii) this Agreement constitutes a valid and binding agreement
enforceable against it in accordance with its terms (except as the enforceability thereof may be limited by bankruptcy, bank moratorium or similar laws affecting creditors’ rights generally and laws restricting the availability of equitable
remedies and may be subject to general principles of equity whether or not such enforceability is considered in a proceeding at law or in equity); and 

(iii) the execution and delivery of this Agreement and all other instruments and documents required to be executed pursuant to this Agreement,
and the consummation of the transactions contemplated hereby do not and shall not (a) conflict with or result in a breach of any provision of its organizational documents, (b) result in a breach of any agreement to which it is a party; or
(c) violate any Applicable Laws. 
 14.2. Representations and Warranties by Noile. Additionally, Noile represents and warrants
that: 
  

	 	(i)	 it solely and exclusively owns or Controls all rights, title and interest in and to the Licensed Patents and
the Licensed Know-How free and clear of any liens, charges and encumbrances; 

  
 - 27 - 

 Confidential 
  

	 	(ii)	 as of the Effective Date, no other person, corporate or other private entity, or government entity or
subdivision thereof, has any claim of ownership whatsoever with respect to the rights under the Licensed Patents and Licensed Know-How; 

 

	 	(iii)	 it has the right to enter into this Agreement and to grant the licenses to Legend hereunder;

  

	 	(iv)	 as of the Effective Date, other than the Licensed Patents and Licensed
Know-How, neither Noile nor its Affiliates owns or controls any patents or know-how that would be necessary or useful for Legend’s performance as contemplated in
this Agreement; 

  

	 	(v)	 all maintenance fees and annual payments due for the Licensed Patents in the Territory have been paid when due;

  

	 	(vi)	 as of the Effective Date it has not received any notice of infringement or any written communication relating
in any way to the possible infringement of any Third Party Intellectual Property by the activities of Noile prior to the Effective Date or by the activities of Legend contemplated by this Agreement; 

 

	 	(vii)	 it shall not knowingly enter into any agreement after the Effective Date which would be inconsistent with its
obligations under this Agreement or deprive Legend of its rights or licenses granted under this Agreement; 

  

	 	(viii)	 as of the Effective Date it has not knowingly granted any licenses to Third Parties or filed any patent
applications inconsistent with the licenses granted to Legend hereunder; 

  

	 	(ix)	 it has provided to Legend, prior to the Effective Date, any and all Clinical Trial data related to the Noile
Platform owned or Controlled by or otherwise known to it or its Affiliates as of the Effective Date; provided, however, that nothing under this Section 14.2(xii) shall require Noile to breach its obligations to any Regulatory Authority under
Applicable Law and/or its confidentiality obligations to any third party under non-disclosure agreements or other similar agreements; and 

 

	 	(x)	 except for [***], it has not been aware of, prior to the Effective Date, any and all passive information or
result concerning [***]. 

 14.3. Nothing in this Agreement shall be construed as: 

(a) a warranty or representation by Noile as to the validity, patentability, scope and/or enforceability of any of the Licensed Patents,
subject to Section 14.2; 

  
 - 28 - 

 Confidential 
  

 (b) a warranty or representation by Noile that any Products made, used, sold, or otherwise
disposed of under any Licensed Patents and Licensed Know-How are or shall be free from infringement of patents or other Intellectual Property rights not licensed hereunder or of Third Parties, subject to
Section 14.2; 
 (c) a warranty or representation by Noile that Intellectual Property rights owned by Third Parties, other than the
Licensed Patents and Licensed Know-How, are not required to formulate, manufacture, sell, or use the Licensed Products, subject to Section 14.2; or 

(d) an obligation of Noile to defend any suit or action brought by a Third Party which challenges or concerns any of the Licensed Patents.

 14.4. Representations and Warranties by Legend. Legend warrants that its Affiliates and Sublicensees shall observe the substance
of the terms and conditions of this Agreement. [***] 
 15. DISCLAIMER AND LIMITATION OF LIABILITY  

15.1. EXCEPT AS EXPRESSLY SET FORTH UNDER SECTIONS 14.1 AND 14.2, NOILE HEREBY EXPRESSLY DISCLAIMS ANY AND ALL REPRESENTATIONS AND WARRANTIES
OF ANY KIND OR NATURE, WHETHER EXPRESS OR IMPLIED, RELATING TO LICENSED PATENTS, LICENSED KNOW-HOW, LICENSED COMPOUNDS, AND LICENSED PRODUCTS, INCLUDING, WITHOUT LIMITATION, ANY WARRANTY OF MERCHANTABILITY,
FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT, VALIDITY, PATENTABILITY, OR ENFORCEABILITY OF LICENSED PATENTS. 

15.2. OTHER THAN AS EXPRESSLY PROVIDED IN SECTION 16, NOILE SHALL NOT BE LIABLE TO LEGEND, INCLUDING ITS AFFILIATES AND SUBLICENSEES, FOR
THIRD PARTY CLAIMS, ACTIONS, AND DAMAGES ARISING OUT OF OR IN CONNECTION WITH THE LICENSED COMPOUNDS AND LICENSED PRODUCTS. 
 15.3. EXCEPT
FOR A PARTY’S BREACH OF ITS OBLIGATIONS UNDER SECTION 7.5 OR SECTION 12, NEITHER PARTY SHALL BE ENTITLED TO CLAIM FROM, OR RECOVER FROM, THE OTHER PARTY, ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL, OR PUNITIVE DAMAGES IN CONNECTION WITH THIS
AGREEMENT. 

  
 - 29 - 

 Confidential 
  

 16. INDEMNIFICATION 

16.1. Indemnification by Legend. Subject to Section 16.3, Legend shall indemnify, defend and hold Noile, its Affiliates and their
respective directors, officers, and employees and the successors and assigns of any of the foregoing harmless from and against any and all liabilities, damages, settlements, penalties, fines, costs or expenses (including reasonable attorneys’
fees and other reasonable expenses of litigation) (collectively, “Loss” or “Losses”) to the extent arising out of or in connection with any Third Party claims, suits, actions, demands or judgments (“Third
Party Claims”) relating to (a) the negligence or willful misconduct of Legend or its Affiliates or any of its or their sub-contractors; and (b) any breach of Applicable Laws by Legend or its
Affiliates, Sublicensees or any of its or their sub-contractors; and (c) any breach of the warranties under Section 14 by Legend or its Affiliates; and (d) infringement of a patent owned by a
Third Party by Legend’s activities under this Agreement ([***]); except, in each case, to the extent caused by the negligence or willful misconduct of Noile or its Affiliates or any of its or their
sub-contractors or breach of this Agreement by Noile or its Affiliates. 
 16.2. Indemnification
by Noile. Subject to Section 16.3, Noile shall indemnify, defend and hold Legend, its Affiliates and their respective directors, officers, and employees and the successors and assigns of any of the foregoing harmless from and against
any and all Losses to the extent arising out of or in connection with any Third Party Claims relating to (a) the negligence or willful misconduct of Noile, its Affiliates or any of its or their
sub-contractor; and (b) any breach of Applicable Laws by Noile, its Affiliates, or any of its or their sub-contractors; and (c) any breach of the warranties
under Section 14 by Noile or its Affiliates; except, in each case, to the extent caused by the negligence or willful misconduct of Legend or its Affiliates or any of its or their sub-contractors or breach
of this Agreement by Legend or its Affiliates. 
 16.3. Indemnification Procedures. If a Party intends to claim indemnification under
this Agreement (the “Indemnitee”), it shall promptly notify the other Party (the “Indemnitor”) in writing of such alleged Loss and the Third Party Claim. The Indemnitor shall have the right to control the defense
thereof with counsel of its choice as long as such counsel is reasonably acceptable to the Indemnitee. The Indemnitee shall have the right to retain its own counsel at its own expense for any reason in connection with such Third Party Claim, [***].
The Indemnitee and its employees and agents shall reasonably cooperate with the Indemnitor and its legal representatives in the investigation of any Third Party Claim covered by this Agreement. The obligations of this Section 16 shall not apply
to any settlement of any Third Party Claim if such settlement is effected without the consent of both Parties, which shall not be unreasonably withheld or delayed. The failure to deliver written notice to the Indemnitor within a reasonable time
after the commencement of any such action, to the extent prejudicial to its ability to defend such action, shall relieve the Indemnitor of any obligation to the Indemnitee under this Section 16.3. It is understood that only Noile and Legend may
claim indemnity under this Agreement (on their own behalf or on behalf of their respective directors, officers, and employees and the successors and assigns of any of the foregoing), and no other party may directly claim indemnity hereunder. 

16.4. Other Infringement. In the event of any patent infringement, misappropriation claim, or suit against either Legend or Noile with
respect to Legend’s activities under this Agreement, including any claim made as part of an arbitration, which is not indemnifiable 

  
 - 30 - 

 Confidential 
  

 
pursuant to this Agreement, each Party shall nevertheless immediately notify the other Party in writing and such other Party shall give the notifying Party reasonable assistance to defend the
said claim or suit and any appeal arising therefrom; provided, however that the notifying Party shall continue, at its own cost and expense, to take all necessary measures and actions to defend the said claim or suit and shall continue to control
such claim, suit and appeal. 
 16.5. Insurance. Each Party shall obtain and maintain comprehensive general liability insurance
customary in the industry for companies of similar size conducting similar business. [***] days after signing this Agreement, each Party shall provide, upon request therefor, the other Party with its certificate of insurance evidencing such
insurance coverage. 
 17. TERM AND TERMINATION 

17.1. This Agreement shall become effective as of the Effective Date and shall, unless terminated sooner as set forth herein, remain in effect
on a country-by-country, Licensed Target-by-Licensed Target, and Licensed Product-by-Licensed Product basis as long as Legend has an obligation to pay the Initial Payments pursuant to Section 9.1, the Milestone Payments pursuant to
Section 9.2, or royalties to Noile pursuant to Section 9.3. After the expiration of this Agreement under this Section 17.1, the exclusive license granted by Noile to Legend under Section 7.3 shall be converted into [***], fully paid-up, irrevocable, royalty-free, and perpetual license. 
 17.2. Legend may terminate this Agreement,
either as a whole, on a country-by country basis, on a Licensed Target-by-Licensed Target basis, or on a Licensed Product-by-Licensed Product basis at any time by giving [***] days’ prior written notice, if in its reasonable judgment, such termination is justified for any reason
including but not limited to commercial, scientific, or medical reasons. 
 17.3. This Agreement may be terminated by either Party at any
time during the life of this Agreement: 
 (a) if it is proven by reasonable evidence that the other Party is in breach of its essential
obligations hereunder by causes and reasons within its control and responsibility and has not cured such default within [***] days after the receipt of written notice identifying the default and requesting its correction; or 

(b) upon filing or institution of bankruptcy, reorganization, liquidation, or receivership proceedings against the other Party. 

17.4. If this Agreement is terminated pursuant to Section 17.2 by Legend or pursuant to Section 17.3 by Noile, then Legend shall
take and/or cause the relevant Affiliates or Sublicensees, unless otherwise agreed upon between the Parties in writing, to take the following measures solely with respect to the relevant countries, relevant Licensed Targets, relevant Licensed
Compounds and relevant Licensed Products, as reasonably applicable: 
 (a) cease to use the Licensed Patents and the non-public, confidential Licensed Know-How, subject to an orderly wind-down, close out of any activity of relevant Licensed Targets and close out of any Clinical Trials of the
Licensed Compounds or the Licensed Products that Legend may have on-going; and 

  
 - 31 - 

 Confidential 
  

 (b) return all the relevant Licensed Know-How
(including remaining materials) supplied by Noile. 
 17.5. If this Agreement is terminated by Legend pursuant to Section 17.3, then
Legend shall take and/or cause its Affiliates or Sublicensees to take the following measures: 
 (a) cease to use the Licensed Patents and
the non-public, confidential Licensed Know-How, subject to an orderly wind-down, close out of any activity of relevant Licensed Targets and close out of any Clinical
Trials of the Licensed Compounds or the Licensed Products that Legend may have on-going; 
 (b)
cease to discover, Develop, make, have made, use, import, export, sell and offer to sell Licensed Products (including Licensed Compounds as applicable); and 

(c) return all the Licensed Know-How supplied by Noile. 

17.6. Any expiration and/or termination of this Agreement for any reason shall be without prejudice to: 

 

	 	(a)	 Noile’s right to receive all payments of the Initial Payments, the Milestone Payments, the royalty
payments, and any other payments accrued before the effective date of the expiration or termination of this Agreement; and 

  

	 	(b)	 the obligation of Legend to keep records provided for in Section 10 above, Noile’s right to examine
records provided for in Section 10.4 above, and Legend’s obligation to furnish tax receipts provided for in Section 10.7 above. 

17.7. In addition to the rights/obligations of the Parties as provided for in Section 17.6 above, termination or expiration of this
Agreement shall not relieve the Parties of any remaining liability, obligations (including indemnification), or rights as shall appropriately survive termination of this Agreement (as specified in the following sentence), nor shall it preclude
either Party from pursuing all rights and remedies it may have hereunder or under Applicable Laws with respect to any breach of this Agreement, nor shall it prejudice any Party’s right to obtain performance of any obligation. The provisions of
Sections 1, 8.2(a), 8.2(b), 10.4, 10.6, 10.7, 11, 12, 13, 14, 15, 16, second sentence of 17.1, 17.4, 17.5, 17.6, 17.7, 17.8, 17.9 and 18 shall survive the expiration or termination of this Agreement; provided however that Sections 8.2(a), 8.2(b) and
second sentence of 17.1 shall not survive in the case where this Agreement was terminated for causes attributable to Legend, including without limitation termination by Legend pursuant to Section 17.2 and termination by Noile pursuant to
Section 17.3. 
 17.8. The license as granted under Section 7 shall forthwith terminate, upon any termination of this Agreement,
except for expiration of the term of this Agreement as provided for in Section 17.1 above. 
 17.9. Notwithstanding anything in this
Section 17 to the contrary, Legend shall have the right to sell and otherwise dispose of the Licensed Products in stock and in the process of being made at the time of early termination of this Agreement for [***] following such termination,
subject to Legend’s compliance with the terms and conditions of this Agreement, specifically including, without limitation, the payment of royalties and the submission of royalty reports with respect to such sale of Licensed Products. 

  
 - 32 - 

 Confidential 
  

 18. MISCELLANEOUS PROVISIONS 

18.1. Amendment. Any amendment or modification of any provision of this Agreement shall be in writing, dated, and signed by each Party.

 18.2. Arbitration.  

(a) Any dispute, controversy, or claim arising under, out of, or relating to this Agreement or any subsequent amendments of this Agreement,
including without limitation its formation, validity, binding effect, interpretation, performance, breach, or termination, as well as non-contractual claims (collectively referred to as
“Disputes”) first shall be attempted to be resolved by discussions between the senior management of the Parties, [***] days following the date on which the Dispute was submitted to them. All negotiations pursuant to this
Section 18.2(a) shall be deemed each Party’s Confidential Information, and shall be treated as settlement negotiations for purposes of any applicable rules of evidence in any subsequent litigation between the Parties relating to such
Dispute. If the Parties’ senior management are unable to resolve such Dispute within [***] period, then either Party may initiate arbitration proceedings in accordance with the provisions of Section 18.2(b) below. 

(b) If a Dispute is not resolved within [***] (or such other period of time mutually agreed upon by the Parties) after the senior management
of the Parties have met as required by Section 18.2(a) above, then it shall be finally resolved by arbitration initiated by either Party and conducted by a [***] under the Rules of Conciliation and Arbitration of the ICC (International Chamber
of Commerce) then in force. The arbitration shall take place [***]. The Parties shall [***]. Failing such agreement, any Party may apply under the applicable rules of the ICC for the appointment of arbitrator(s) and the selection of arbitrator(s)
under such rules of the ICC shall be final and binding on the Parties. All such arbitrator(s) shall have appropriate experience in the pharmaceutical industry and be independent of all the Parties. The Parties shall [***] after the arbitrator(s)
have been appointed. The award shall be final and binding upon the Parties, and judgment upon the award may be entered in any court having jurisdiction thereof. [***] The arbitrators shall examine arguments and evidence by each Party and resolve
each of the issues identified by the Parties. The panel of arbitrators shall render a formal, binding non-appealable resolution and award on each issue as expeditiously as possible. In any arbitration,
discovery shall be permitted subject to the arbitrators’ reasonable judgment, and each Party shall voluntarily produce to the other all documents such Party shall use in its portion of the arbitration. The arbitrators shall have no power to
include an award of attorneys’ fees and costs to the prevailing Party, or to award punitive, special, incidental or consequential damages. All rulings of the panel of arbitrators 

  
 - 33 - 

 Confidential 
  

 
shall be in writing and shall be delivered to the Parties. Each Party shall bear its own costs for its counsel and other expenses, and the Parties shall equally share the costs of the
arbitration. Judgment upon the award may be entered in any court having jurisdiction, or application may be made to such court for judicial acceptance of the award and/or an order of enforcement as the case may be. Notwithstanding the foregoing,
this Section 18.2 shall not apply to any disputes relating to a Party’s patent rights (including the validity or infringement of patents or scope of patent claims), which instead shall be resolved by a court or the patent office (or its
equivalent) of competent jurisdiction. 
 18.3. Assignment. Neither Party may assign or transfer this Agreement or any right or
obligation hereunder to any Third Party without the prior written consent of the other Party, except that either Party may assign this Agreement to an Affiliate or to an assignee or successor to all or substantially all of its business or assets
without the consent of the other Party. This Agreement is binding upon and shall inure to the benefit of the Parties, their representatives, and permitted assigns. 

18.4. Captions. The captions and section headings used in this Agreement are for convenience only and are not intended to have, nor
shall they be interpreted as having, any substantive effect whatsoever. 
 18.5. Entire Agreement. This Agreement embodies the entire
understanding between the Parties relating to the subject matter hereof, and there are no prior representations, warranties, or agreements, whether written or oral, between the Parties, not contained in this Agreement. 

18.6. Force Majeure. Neither of the Parties shall be liable for any default in performance of this Agreement due to the occurrence of
any event beyond the reasonable control of the affected Party, including, but not limited to, enactment or change of government laws, regulations, or orders, an act of God, fire, storm, earthquake, act of terrorism, labor disturbances, war, and riot
(defined as “Force Majeure” herein). On the occurrence of any event of Force Majeure, the affected Party shall give notice and full particulars of such event of Force Majeure to the other Party as soon as practicable and shall exert
[***] to remedy the situation. In the meantime, the Parties hereto shall consult with each other [***]. 
 18.7. Governing Law. This
Agreement shall be governed by and construed in accordance with the laws of [***] without reference to any rules of conflict of laws. This Agreement was prepared in the English language, which language shall govern the interpretation of, and any
dispute regarding, the terms of this Agreement. 
 18.8. Notice. Any notice or communication in connection with this Agreement shall
be made in the English language and considered sufficient if in writing and personally delivered to an officer of the Party for which it is intended, or if sent first by facsimile or email and confirmed by registered air mail or special courier at
the address specified below or such other address as the Party has given notice of in writing. It shall (except as otherwise provided in this Agreement) be deemed to have been received (a) when delivered, if personally delivered and (b) on
the [***] day after dispatch, if sent 

  
 - 34 - 

 Confidential 
  

 
by facsimile or nationally-recognized express delivery service; provided that any legal process served in such manner pursuant to this Section shall be deemed to have been received only when
actually delivered, unless otherwise provided by Applicable Law. All notices shall be deemed effective upon actual receipt by a Party to whom such notices are given. 

If to Noile: 
 [***] 

With required copy to: 
 [***]

 If to Legend: 
 [***] 

With required copies to: 
 [***]

 and 
 [***] 

Either Party may change its address or facsimile number by notice to the other Party pursuant to this Section 18.8. 

18.9. Severability. If any provision of this Agreement is declared invalid or unenforceable by a court having competent jurisdiction,
it is mutually agreed that this Agreement shall endure except for the part declared invalid or unenforceable by orders of such a court. The Parties shall consult and make their best efforts to agree upon a valid and enforceable provision which shall
be a reasonable substitute for such invalid or unenforceable provision in light of the intent of this Agreement. 
 18.10. Waivers. A
waiver by either Party of any term or condition of this Agreement in any one instance shall not be deemed to continue to be a waiver of such a term or condition for any similar instance in the future or of any subsequent breach thereof or of any
other term or condition of this Agreement. 

  
 - 35 - 

 Confidential 
  

 18.11. Counterparts. This Agreement may be executed in any number of counterparts and
each such counterpart shall be deemed to be an original. 
 IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed and delivered
by their respective duly authorized representatives as of the date first above written. 
  

									
	Noile-Immune Biotech, Inc.	 		 	Legend Biotech USA, Inc.
					
	By:	 	/s/ Hidenobu Ishizaki	 		 	By:	 	/s/ Meeta Chatterjee
		 	Hidenobu Ishizaki,	 		 		 	Meeta Chatterjee
		 	President & CEO	 		 		 	Senior Vice President, Global Business Development
			
	Date: April 27, 2020	 		 	Date: April 27, 2020

  
 - 36 - 

 Confidential 
  

 EXHIBIT A 

Noile Patents 
 [***] 

  
 - i - 

 Confidential 
  

 EXHIBIT B 

Noile’s Bank Account 
 [***] 

  
 - iv -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00309-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00309-of-00352.parquet"}]]